Ker, K; Tansley, G; Beecher, D; Perner, A; Shakur, H; Harris, T; Roberts, I (2015) Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease. The Cochrane database of systematic reviews, 2. CD011386. ISSN 1469-493X DOI: https://doi.org/10.1002/14651858.CD011386.pub2

Downloaded from: http://researchonline.lshtm.ac.uk/2162890/

DOI: 10.1002/14651858.CD011386.pub2

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease
(Review)

Ker K, Tansley G, Beecher D, Perner A, Shakur H, Harris T, Roberts I

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 2

http://www.thecochranelibrary.com

WILEY
**TABLE OF CONTENTS**

- HEADER .......................................................... 1
- ABSTRACT .......................................................... 1
- PLAIN LANGUAGE SUMMARY .................................... 2
- SUMMARY OF FINDINGS FOR THE MAIN COMPARISON ....... 4
- BACKGROUND ....................................................... 6
- OBJECTIVES ....................................................... 6
- METHODS .......................................................... 7
- RESULTS ........................................................... 9
  - Figure 1 .......................................................... 10
  - Figure 2 .......................................................... 13
- ADDITIONAL SUMMARY OF FINDINGS ......................... 21
- DISCUSSION ....................................................... 26
- AUTHORS' CONCLUSIONS ....................................... 27
- ACKNOWLEDGEMENTS ............................................ 28
- REFERENCES ...................................................... 28
- CHARACTERISTICS OF STUDIES ................................. 31
- DATA AND ANALYSES ............................................. 58
  - Analysis 1.1. Comparison 1 Intravenous versus intraosseous access, Outcome 1 Insertion failures ............ 60
  - Analysis 1.2. Comparison 1 Intravenous versus intraosseous access, Outcome 2 Insertion failures (subgroup analysis child vs adult) .......................................................... 60
  - Analysis 1.3. Comparison 1 Intravenous versus intraosseous access, Outcome 3 Time to infusion/placement .. 62
  - Analysis 1.4. Comparison 1 Intravenous versus intraosseous access, Outcome 4 Average number of insertion attempts .......................................................... 62
  - Analysis 1.5. Comparison 1 Intravenous versus intraosseous access, Outcome 5 Dislodgement of device during infusion .......................................................... 63
  - Analysis 1.6. Comparison 1 Intravenous versus intraosseous access, Outcome 6 Local site reactions ............ 63
  - Analysis 1.7. Comparison 1 Intravenous versus intraosseous access, Outcome 7 Clinician's perception of ease/feasibility of administration ........................................... 64
  - Analysis 1.8. Comparison 1 Intravenous versus intraosseous access, Outcome 8 Volume of fluids transfused ... 64
  - Analysis 1.9. Comparison 1 Intravenous versus intraosseous access, Outcome 9 Electrolyte level ................ 65
  - Analysis 1.10. Comparison 1 Intravenous versus intraosseous access, Outcome 10 Renal function ............... 65
  - Analysis 2.1. Comparison 2 Intravenous versus subcutaneous access, Outcome 1 Insertion failures ........... 66
  - Analysis 2.2. Comparison 2 Intravenous versus subcutaneous access, Outcome 2 Insertion failures (sensitivity analysis - trial(s) with adequate allocation concealment) .............. 66
  - Analysis 2.3. Comparison 2 Intravenous versus subcutaneous access, Outcome 3 Insertion failures (subgroup analysis child vs adult) .......................................................... 66
  - Analysis 2.4. Comparison 2 Intravenous versus subcutaneous access, Outcome 4 Time to infusion/placement .. 68
  - Analysis 2.5. Comparison 2 Intravenous versus subcutaneous access, Outcome 5 Dislodgement of device during infusion .......................................................... 68
  - Analysis 2.6. Comparison 2 Intravenous versus subcutaneous access, Outcome 6 Time with functional access (days) .......................................................... 69
  - Analysis 2.7. Comparison 2 Intravenous versus subcutaneous access, Outcome 7 Local site reactions ............ 69
  - Analysis 2.8. Comparison 2 Intravenous versus subcutaneous access, Outcome 8 Local site reactions (sensitivity analysis - trial(s) with adequate allocation concealment) .............. 71
  - Analysis 2.9. Comparison 2 Intravenous versus subcutaneous access, Outcome 9 Clinicians' scores of feasibility of insertion .......................................................... 73
  - Analysis 2.10. Comparison 2 Intravenous versus subcutaneous access, Outcome 10 Clinician's perception of difficulty of insertion .......................................................... 73
  - Analysis 2.11. Comparison 2 Intravenous versus subcutaneous access, Outcome 11 Patients' discomfort ........... 74
  - Analysis 2.12. Comparison 2 Intravenous versus subcutaneous access, Outcome 12 Patients' discomfort (sensitivity analysis - trial(s) with adequate allocation concealment) .............. 75
  - Analysis 2.13. Comparison 2 Intravenous versus subcutaneous access, Outcome 13 Patient discomfort score .... 75
  - Analysis 2.14. Comparison 2 Intravenous versus subcutaneous access, Outcome 14 Mortality ....................... 76
  - Analysis 2.15. Comparison 2 Intravenous versus subcutaneous access, Outcome 15 Mortality (sensitivity analysis - trial(s) with adequate allocation concealment) .............. 76

---

Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease (Review)  
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Katharine Ker¹, Gavin Tansley², Deirdre Beecher³, Anders Perner³, Haleema Shakur², Tim Harris⁴, Ian Roberts¹

¹Cochrane Injuries Group, London School of Hygiene & Tropical Medicine, London, UK. ²Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK. ³ITA 4131/Department of Intensive Care, Rigshospitalet, Copenhagen, Denmark. ⁴Department of Emergency Medicine, Royal London Hospital, Barts Health NHS Trust, London, UK

Contact address: Katharine Ker, Cochrane Injuries Group, London School of Hygiene & Tropical Medicine, Room 186, Keppel Street, London, WC1E 7HT, UK. katharine.ker@lshtm.ac.uk.

Editorial group: Cochrane Injuries Group.
Review content assessed as up-to-date: 17 November 2014.


ABSTRACT

Background
Dehydration is an important cause of death in patients with Ebola virus disease (EVD). Parenteral fluids are often required in patients with fluid requirements in excess of their oral intake. The peripheral intravenous route is the most commonly used method of parenteral access, but inserting and maintaining an intravenous line can be challenging in the context of EVD. Therefore it is important to consider the advantages and disadvantages of different routes for achieving parenteral access (e.g. intravenous, intraosseous, subcutaneous and intraperitoneal).

Objectives
To compare the reliability, ease of use and speed of insertion of different parenteral access methods.

Search methods
We ran the search on 17 November 2014. We searched the Cochrane Injuries Group’s Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library), Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily, Ovid MEDLINE(R) and Ovid OLDMEDLINE(R), Embase Classic + Embase (OvidSP), CINAHL (EBSCOhost), clinicaltrials.gov and screened reference lists.

Selection criteria
Randomised controlled trials comparing different parenteral routes for the infusion of fluids or medication.

Data collection and analysis
Two review authors examined the titles and abstracts of records obtained by searching the electronic databases to determine eligibility. Two review authors extracted data from the included trials and assessed the risk of bias. Outcome measures of interest were success of insertion; time required for insertion; number of insertion attempts; number of dislodgements; time period with functional access; local site reactions; clinicians’ perception of ease of administration; needlestick injury to healthcare workers; patients’ discomfort; and mortality. For trials involving the administration of fluids we also collected data on the volume of fluid infused, changes in serum
electrolytes and markers of renal function. We rated the quality of the evidence as 'high', 'moderate', 'low' or 'very low' according to the GRADE approach for the following outcomes: success of insertion, time required for insertion, number of dislodgements, volume of fluid infused and needlestick injuries.

Main results

We included 17 trials involving 885 participants. Parenteral access was used to infuse fluids in 11 trials and medications in six trials. None of the trials involved patients with EVD. Intravenous and intraosseous access was compared in four trials; intravenous and subcutaneous access in 11; peripheral intravenous and intraperitoneal access in one; saphenous vein cutdown and intraosseous access in one; and intraperitoneal with subcutaneous access in one. All of the trials assessing the intravenous method involved peripheral intravenous access.

We judged few trials to be at low risk of bias for any of the assessed domains.

Compared to the intraosseous group, patients in the intravenous group were more likely to experience an insertion failure (risk ratio (RR) 3.89, 95% confidence interval (CI) 2.39 to 6.33; n = 242; GRADE rating: low). We did not pool data for time to insertion but estimates from the trials suggest that inserting intravenous access takes longer (GRADE rating: moderate). Clinicians judged the intravenous route to be easier to insert (RR 0.15, 95% CI 0.04 to 0.61; n = 182). A larger volume of fluids was infused via the intravenous route (GRADE rating: moderate). There was no evidence of a difference between the two routes for any other outcomes, including adverse events.

Compared to the subcutaneous group, patients in the intravenous group were more likely to experience an insertion failure (RR 14.79, 95% CI 2.87 to 76.08; n = 238; GRADE rating: moderate) and dislodgement of the device (RR 3.78, 95% CI 1.16 to 12.34; n = 67; GRADE rating: low). Clinicians also judged the intravenous route as being more difficult to insert and patients were more likely to be agitated in the intravenous group. Patients in the intravenous group were more likely to develop a local infection and phlebitis, but were less likely to develop erythema, oedema or swelling than those in the subcutaneous group. A larger volume of fluids was infused into patients via the intravenous route. There was no evidence of a difference between the two routes for any other outcome.

There were insufficient data to reliably determine if the risk of insertion failure differed between the saphenous vein cutdown (SVC) and intraosseous method (RR 4.00, 95% CI 0.51 to 31.13; GRADE rating: low). Insertion using SVC took longer than the intraosseous method (MD 219.60 seconds, 95% CI 135.44 to 303.76; GRADE rating: moderate). There were no data and therefore there was no evidence of a difference between the two routes for any other outcome.

There were insufficient data to reliably determine the relative effects of intraperitoneal or central intravenous access relative to any other parenteral access method.

Authors' conclusions

There are several different ways of achieving parenteral access in patients who are unable meet their fluid requirements with oral intake alone. The quality of the evidence, as assessed using the GRADE criteria, is somewhat limited because of the lack of adequately powered trials at low risk of bias. However, we believe that there is sufficient evidence to draw the following conclusions: if peripheral intravenous access can be achieved easily, this allows infusion of larger volumes of fluid than other routes; but if this is not possible, the intraosseous and subcutaneous routes are viable alternatives. The subcutaneous route may be suitable for patients who are not severely dehydrated but in whom ongoing fluid losses cannot be met by oral intake.

A film to accompany this review can be viewed here (http://youtu.be/ArVPzkf93ng).

PLAIN LANGUAGE SUMMARY

Comparison of the different ways of giving fluids to patients who cannot drink enough, such as patients with Ebola virus disease

Background

Many patients with Ebola virus disease (EVD) die because they are dehydrated. Patients with EVD often experience severe vomiting and diarrhoea, which causes them to lose fluids that are difficult to replace by drinking alone. It is possible to give fluids in ways that do not involve the digestive tract; this is known as parenteral access. This includes infusing fluids into a vein (intravenously), into bone marrow (intraosseously), into fatty tissue under the skin (subcutaneously) or into the abdominal space (intraperitoneally). Giving fluids
intravenously is the usual method, but can be problematic in patients with EVD because starting intravenous fluids can be difficult in very dehydrated patients, and infection control practices may make maintaining the infusion challenging. It is therefore useful if those caring for patients with EVD know the advantages and disadvantages of the other ways to give fluids, so that they can decide which is the most suitable for their patients.

**Searches for trials**

We carried out searches for trials comparing different parenteral access methods on 17 November 2014.

**Trial characteristics**

We found 17 trials involving 885 participants. None involved patients with EVD. Fifteen trials involved patients who required parenteral access for the infusion of fluids or medicines and two trials assessed different methods under simulated conditions, such as on a training manikin. Many trials were of poor quality.

**Key results**

When the results of these trials were gathered together, they suggested that both the intraosseous and subcutaneous routes may be easier and quicker to insert into patients than the intravenous route, but more fluid can be given intravenously than by either the intraosseous or subcutaneous method. There has not been enough research into the intraperitoneal method to know how it compares to the other methods.

**Conclusions**

Healthcare workers caring for patients with EVD should be aware of the alternative ways of giving fluids. The trials we found were not of very high quality, therefore we need to be cautious when drawing conclusions based on their results. However, together they suggest if intravenous access can be achieved easily, then this should be used as it allows the infusion of larger volumes of fluid. However, if intravenous access is not possible, intraosseous and subcutaneous routes are alternatives that can be inserted quickly. Many of the trials conducted so far are of poor quality and none involved patients with EVD, therefore more trials should be carried out.

A film to accompany this review can be viewed here.
### Summary of Findings for the Main Comparison

#### Intravenous versus Intraosseous Route for Achieving Parenteral Access

**Patient or Population:** Adults or children requiring fluid delivered by a parenteral route (one study testing insertion and the volume of fluid delivered in manikins by practitioners wearing protective equipment was also included)  
**Settings:** India (emergency unit) and USA (prehospital care)  
**Intervention:** Intravenous route  
**Comparison:** Intraosseous route

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative risks* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No of participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assumed risk</strong></td>
<td><strong>Corresponding risk</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intraosseous route</td>
<td>Intravenous route</td>
<td>RR 3.89 (2.39 to 6.33)</td>
<td>242 (2 RCTs)</td>
<td>✽✽✽ ⃝⃝ LOW 1,2</td>
<td></td>
</tr>
<tr>
<td>Insertion failures</td>
<td>Study population</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 per 100</td>
<td>47 per 100 (29 to 76)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time to infusion/placement</td>
<td>We did not combine data due to substantial variation in the average time taken to insert parenteral access between trials. The estimates from all 4 trials suggest that the IV route takes longer to insert than IO. Although we are confident that the time to infusion is shorter with IO, we cannot be certain about the size of the effect because the magnitude of the difference varied considerably between trials.</td>
<td>-</td>
<td>342 (4 RCTs)</td>
<td>✽✽✽MODERATE 1.</td>
<td></td>
</tr>
<tr>
<td>Dislodgement of device during infusion</td>
<td>Study population</td>
<td>RR 0.53 (0.18 to 1.55)</td>
<td>182 (1 RCT)</td>
<td>✽✽✽ LOW 1,3</td>
<td></td>
</tr>
<tr>
<td>113 per 1000</td>
<td>60 per 1000 (20 to 175)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Needlestick injuries</td>
<td>No studies reported this outcome</td>
<td>-</td>
<td>NA</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

*GRADE: LOW = low-quality evidence, MODERATE = moderate-quality evidence, HIGH = high-quality evidence.*
| Volume of fluid infused | The mean volume of fluid infused (ml) in the IO group was 800 | The mean volume of fluid infused (ml) in the IV group was 400 higher (365 higher to 434 higher) | - | 182 (1 RCT) | MODERATE 1 |

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; IO: intraosseous; IV: intravenous; NA: not applicable; RCT: randomised controlled trial; RR: risk ratio

GRADE Working Group grades of evidence

- **High quality:** Further research is very unlikely to change our confidence in the estimate of effect.
- **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
- **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
- **Very low quality:** We are very uncertain about the estimate.

1. Downgraded one level for risk of bias: estimate based on trial(s) at unclear and/or high risk of bias for > 1 domain.
2. Downgraded one level for imprecision: estimate is statistically significant at the 5% level (P value <0.001); however, the estimated required information size has not been achieved and we cannot discount the possibility that it is a false positive.
3. Downgraded one level for imprecision: estimate based on few events and wide CIs that include both an increase and a decrease in risk.
BACKGROUND

Description of the condition

Ebola virus disease (EVD) is a severe infection with a high case-fatality rate (WHO Ebola Response Team 2014). West Africa is currently (November 2014) experiencing the largest recorded outbreak of EVD with many hundreds of new cases per week (WHO Ebola Response Team 2014). EVD is characterised by sudden onset of fever followed by nausea, vomiting and diarrhoea. The associated fluid loss, which can be as much as five to 10 litres per day (Kreuels 2014; Ribner 2014), leads to electrolyte abnormalities and profound intravascular volume depletion (Feldmann 2011; Sanchez 2006). Case series show that in people with fatal EVD, blood levels of urea and creatinine increase over time, which may be a consequence of dehydration (Schiefelin 2014). Fluid administration is therefore recommended as a key part of supportive care to reduce mortality in patients with EVD (WHO 2014).

Description of the intervention

Many patients with EVD have nausea, difficulty swallowing and severe vomiting, which limit the usefulness of oral rehydration. Similarly, severe diarrhoea limits the usefulness of rectal fluid administration. In these patients, parenteral fluids can be given to prevent and treat dehydration.

There are four main ways of achieving parenteral access to administer fluids: intravenous, intraosseous, subcutaneous and intraperitoneal.

- Intravenous access involves the delivery of fluids or medications directly into a vein. There are two types of venous access - central and peripheral. Central venous catheters involve placing a cannula into one of the large veins as it enters the body’s trunk (most commonly the internal jugular, subclavian or femoral veins) and advancing until the tip of the catheter sits in the superior vena cava, or the iliac vein in the case of the femoral catheter. Peripheral cannulae are placed in a limb or (rarely) the scalp;

- Intraosseous access involves the insertion of a needle into the bone marrow (usually in the tibia or the humerus, or less commonly in the pelvis or sternum) to which an infusion line is connected. It is often used in patients for whom intravenous access is difficult to achieve, such as those with collapsed peripheral veins and young children. Intraosseous needles can be inserted manually, although the use of mechanical insertion devices, such as the BIG Bone Injection Gun® and Arrow® EZ-IO® Intraosseous Vascular Access System, have become common. A pressurised fluid bag is required to ensure that the fluid runs;

- Subcutaneous access involves the insertion of a needle or catheter into the subcutaneous tissue that lies beneath the dermis and epidermis layers. Hyaluronidase may be given to improve absorption of infused substances into the circulation. Common sites for subcutaneous infusion are the abdomen, thigh and upper arm;

- Intraperitoneal access involves placing a catheter through the abdominal wall and the delivery of fluids into the peritoneal cavity, in similarity with peritoneal dialysis. This approach has been used in resource poor settings to resuscitate children with severe diarrhoea due to cholera infection (Mahalanabis 1970).

The intravenous route is the most commonly used method for administering fluids (Wait 2004). However, securing intravenous access can be technically difficult in sick and dehydrated patients and is likely to be particularly challenging for healthcare workers obliged to wear personal protective equipment (PPE). Staff shortages and limitation of time spent at the bedside due to the challenge of wearing PPE for long periods in a hot environment may also frustrate efforts to achieve intravenous access in large numbers of sick patients (Fowler 2014). Securing parenteral access may also present risks to healthcare workers, e.g. needlestick injury or inadvertent contact with body fluids associated with insertion or dislodgement of parenteral access. For these reasons, an understanding of the relative merits of alternative routes (intravenous, intraosseous, subcutaneous or intraperitoneal) for achieving parenteral access could be important for the management of patients with EVD. The different approaches are likely to vary in terms of ease of insertion and effectiveness for fluid replacement.

Why it is important to do this review

Due to the large number of cases and resource constraints, it is essential that parenteral access in patients with EVD can be achieved quickly and maintained with minimal clinical intervention. We have therefore conducted a systematic review of randomised controlled trials comparing alternative routes for achieving parenteral access to assess their effectiveness and safety in terms of ease of insertion and effectiveness for fluid replacement. This Cochrane review has been prompted by the ongoing EVD crisis in West Africa and the need to identify ways to improve the medical care of those affected. However, we have not limited the inclusion criteria to patients with EVD as we anticipated that it was unlikely that we would find any trial research conducted in this specific patient group. We believe that evidence derived from trials involving patients who require insertion of parenteral access for other indications is relevant to the management of patients with EVD, as well as to the wider range of patients who require parenteral infusions.

OBJECTIVES
To compare the reliability, ease of use and speed of insertion of different parenteral access methods.

**METHODS**

Criteria for considering studies for this review

Types of studies
Randomised controlled trials.
Eligible trials were those judged to have assigned participants using a method of random allocation (e.g. computer-generated randomisation, random numbers table or drawing lots) or a quasi-random method of allocation (e.g. alternation, date of birth or case record number) (definition adapted from Box 6.3.a in Lefebvre 2011).

Types of participants
People of any age in whom insertion of a parenteral access method is attempted for the purpose of infusing fluids or medication. Trials involving the insertion of parenteral access under simulated conditions, such as using manikins or cadavers in which healthcare workers are randomly allocated to insert different parenteral access methods, were also eligible.

Types of interventions
We considered the following parenteral access methods: intravenous (central venous access and peripheral venous access), intraperitoneal, subcutaneous and intraosseous (using both manual and mechanical methods). We planned to explore the effects of central venous access and peripheral venous access separately. Only trials comparing two or more of the above parenteral routes were eligible.

Types of outcome measures

Primary outcomes
- Success of route placement (‘success’/‘failure’ as defined in the individual trial).

Secondary outcomes
- Time to infusion/placement.
- Average number of insertion attempts.
- Dislodgement of device during infusion.
- Time period with functional access.
- Local site reactions (e.g. infusion site pain, swelling, infection).
- Clinician’s perception of ease of administration.
- Needlestick injury to healthcare workers.
- Patient’s discomfort.
- Mortality.

For trials assessing parenteral routes for fluid administration, we extracted data on the following outcomes:
- Volume of fluid infused.
- Electrolyte levels and renal function (changes in serum sodium, potassium, urea and creatinine).

Search methods for identification of studies
In order to reduce publication and retrieval bias we did not restrict our search by language, date or publication status.

Electronic searches
We searched the following databases:
1. Cochrane Injuries Group Specialised Register (17 November 2014);
2. Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library) (issue 10 of 12, 2014);
3. Ovid MEDLINE(R), Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid OLDMEDLINE(R) (1946 to 17 November 2014);
4. Embase Classic + Embase (OvidSP) (1947 to 17 November 2014);
5. CINAHL Plus (EBSCO) (1937 to 17 November 2014);

We adapted the MEDLINE search strategy (Appendix 1) as necessary for each of the other databases: the added study filter is a modified version of the Ovid MEDLINE(R) Cochrane Highly Sensitive Search Strategy for identifying randomised trials (Lefebvre 2011). For the Embase search strategy we added the study design terms used by the UK Cochrane Centre (Lefebvre 2011).

Searching other resources
We screened the reference lists of the eligible trials and review articles for further potentially eligible studies. We also searched the internet using the Google search engine (www.google.com) with selected terms from the search strategy to identify further unpublished or grey literature.

Data collection and analysis

Selection of studies
Two review authors (KK and DB, IR or HS) independently examined the records identified from the search and screened them by
We assessed the following. Where there were multiple (assuming an estimate of the intracluster correlation), we resolved any disagreements about the extracted data by discussing or by asking a third review author (IR).

**Data extraction and management**
Two review authors (KK and GT) independently extracted data using a data extraction form designed specifically for the review. We extracted data on the following:
- patient characteristics (including age, sex, indication for parenteral access);
- intervention characteristics (including description of parenteral routes, use of PPE);
- trial methods (specifically information for 'Risk of bias' assessment);
- outcome data.
We resolved any disagreements about the extracted data by discussion or by asking a third review author (IR).

**Assessment of risk of bias in included studies**
Two review authors (KK and GT) assessed the risk of bias in the included trials using The Cochrane Collaboration’s 'Risk of bias' tool, as described by Higgins 2011a. We assessed the following domains for each trial: sequence generation, allocation concealment, blinding (participants, personnel and outcome assessment), incomplete outcome data and selective outcome reporting. We completed a 'Risk of bias' table, incorporating a description of the trial against each of the domains and a judgement of the risk of bias, as follows: 'low risk', 'high risk' or 'unclear risk' of bias. For the 'blinding of outcome assessment' and 'incomplete outcome data' domains, we assessed the risk of bias by outcome group as follows.
- Outcomes related to parenteral route insertion (success of route placement; number of insertion attempts; dislodgement of device during infusion; time period with functional access).
- Clinical outcomes (sodium; potassium; urea; creatinine; mortality).
- Subjective outcomes (local site reactions, complications; clinician's perception of ease of administration; volume of fluid infused; needlestick injury to healthcare workers; patient's discomfort).

**Measures of treatment effect**
For binary outcome data, we calculated risk ratios and 95% confidence intervals (CI) and for continuous outcome data we calculated the mean difference and 95% CI for each trial. In a number of trials, summary continuous data were presented as medians and ranges; in these cases, for the purpose of meta-analysis, we estimated the corresponding means and standard deviations using the method described in Hozo 2005 (Appendix 2).

**Unit of analysis issues**
For cross-over trials, we extracted effect estimates from an appropriate paired analysis from the trial reports or we calculated these where possible. We included these estimates in the meta-analysis using the generic inverse variance method. However, if a cross-over trial presented data according to the treatment group, we analysed the results from both periods of the cross-over trial as if they had originated from a parallel design. This latter approach leads to a unit of analysis error, causing the CIs to be too wide and the trial to receive too little weight. However, we think that the resulting conservative estimates are preferable to omitting all such data from the analyses.

Cluster-randomised controlled trials that reported effect estimates and confidence intervals derived from an appropriate analysis (e.g. generalised estimating equations or multi-level modelling) would have been included in the meta-analysis using the generic inverse variance method. Alternatively, if any such trial had analysed data at the level of the participant rather than at the cluster level, we would have attempted an approximate analysis as described in Higgins 2011b, assuming an estimate of the intracluster correlation coefficient was available.

For trials involving multiple intervention groups, we followed the approach described in Higgins 2011b. Where there were multiple groups receiving the same parenteral access method, we combined these to create a single pair-wise comparison with a group receiving an alternative parenteral method.

**Dealing with missing data**
We analysed trial results on an intention-to-treat basis where the necessary data were available. Where data in the trial reports were not presented on an intention-to-treat basis but information about exclusions was presented, we ‘re-included’ exclusions to allow for inclusion in the meta-analysis as intention-to-treat. Otherwise, we used the data available from the trial report and conducted an available-case analysis.

**Assessment of heterogeneity**
We assessed trial characteristics in terms of participants, interventions and outcomes for clinical heterogeneity. We examined statistical heterogeneity by visual inspection of forest plots, and by using the I² statistic and the Chi² test. The I² statistic describes the percentage of total variation across studies due to heterogeneity rather than chance. A value of 0% indicates no observed heterogeneity and larger values show increasing heterogeneity; substantial heterogeneity is considered to exist when I² is greater than 50% (Deeks 2011). For the Chi² test, we used a P value of less than 0.10 to indicate the presence of statistically significant heterogeneity.
We anticipated that differences in the definition of the primary outcome, 'success'/'failure' of insertion, between individual trials might be a potential source of heterogeneity.
Assessment of reporting biases
We planned to investigate the presence of reporting (publication) bias using funnel plots if there were at least 10 trials for the same outcome in the analysis.

Data synthesis
Where we judged the included trials to be too clinically heterogeneous to pool, we described the results narratively. When we considered a pooled analysis to be appropriate, we combined effect estimates using the fixed-effect model (also known as the weighted-average method). We consider this approach to be preferable to the random-effects model, which can give too much weight to smaller trials that are often of poorer methodological quality.

Required sample size
Using TSA - Trial Sequential Analysis 0.9 Beta software, we estimated that a total sample size of 1388 would be required for the meta-analysis of our primary outcome to detect an intervention effect reliably. This estimate is based on an assumed baseline event rate of 50%, with 90% power to detect a clinically relevant difference of 20% at the 5% significance level, adjusted for heterogeneity anticipated at $I^2 = 25\%$.

Subgroup analysis and investigation of heterogeneity
We conducted subgroup analyses to examine whether the effects of the parenteral route of fluid administration varied by age of patient (child versus adult) and use of PPE (PPE versus no PPE), assuming that there was at least one trial in each subgroup.

Sensitivity analysis
We conducted sensitivity analyses to quantify the effects when restricted to trials with adequate allocation concealment, assuming that there was at least one trial contributing data to the analysis.

Summary of findings
We have also included the results of the review for the following outcomes in 'Summary of findings' tables. We included information about the following outcomes:
- success of route placement;
- time to placement/start to infusion;
- dislodgement of device during infusion;
- volume of fluid infused;
- needlestick injuries.

We used GRADEpro 2014 to prepare the tables. We judged the overall quality of the evidence for each outcome as 'high', 'moderate', 'low' or 'very low' according to the GRADE approach (Schünemann 2011). We considered the following:
- impact of the risk of bias of individual trials;
- precision of the pooled estimate;
- inconsistency or heterogeneity (clinical, methodological and statistical);
- indirectness of evidence;
- impact of selective reporting and publication bias on effect estimate.

RESULTS

Description of studies

Results of the search
The trial selection process is summarised in Figure 1. The combined search strategy identified 1276 records, of which we judged 36 to be potentially eligible and obtained the full texts. After a full-text review, we included 17 trials in the review, which involved 21 eligible pair-wise comparisons.
Figure 1. Study flow diagram.

Records identified through database searching (n = 1615)  Additional records identified through other sources (n = 2)

Records after duplicates removed (n = 1276)

Records screened (n = 1276)  Records excluded (n = 1243)

Full-text articles assessed for eligibility (n = 33)  Full-text articles excluded (n = 15)

Studies included in qualitative synthesis (n = 17 studies reported in 18 articles)

Studies included in quantitative synthesis (meta-analysis) (n = 12)
Included studies
Full details of each trial are presented in the Characteristics of included studies table; a summary is given below.

Design
Ten trials were randomised, parallel-group trials and seven were randomised, cross-over trials. Of the seven cross-over trials, five involved a two-period comparison, one a four-period comparison and one a three-period comparison.

Sample sizes
The 17 trials included a combined total of 885 participants, of whom 847 were patients requiring parenteral access and 38 were health personnel who were attempting parenteral access under simulated conditions. The median sample size was 37 (range 6 to 182). One hundred and five participants were included in the cross-over trials and therefore acted as their own control.

Setting and participants
One trial was multicentre, conducted in 11 European countries. The remaining trials were conducted in Denmark (n = 1), France (n = 5), Germany (n = 1), India (n = 1), Spain (n = 1), Sweden (n = 1), the USA (n = 3) and the UK (n = 3).

None of the included trials involved patients with Ebola virus disease (EVD) or were conducted in the context of a similar medical emergency. Instead, the included trials were conducted in the following clinical settings: two involved the treatment of children with dehydration in hospital; one involved patients receiving a bone marrow transplant; six involved hospitalised elderly patients requiring parenteral fluids to maintain or restore hydration; three involved the infusion of insulin in patients with diabetes; one involved patients with multifocal neuropathy being treated with immunoglobulin; one involved patients with malignant disease in an oncology department; one involved paramedics attending out-of-hospital cardiac arrests; one involved paramedic trainees attempting parenteral access on cadavers in a hospital training laboratory; and one involved doctors and nurses attempting parenteral access on manikins in a pre-hospital department.

Fifteen trials compared different parenteral routes in patients; 14 involved adults and one involved children (Banerjee 1994). The other two studies by Lamhaut et al and Hubble 2001 used a cross-over design to assign medical personnel to attempt different parenteral routes. Training manikins were used in Lamhaut and cadavers in Hubble 2001.

The purpose of the parenteral access was for the infusion of fluids in 11 trials (Banerjee 1994; Challiner 1994; Dardaine 1995; Delamaire 1992; Duemns Noriega 2014; Hubble 2001; Lamhaut 2010 (no PPE); Lamhaut 2010 (with PPE); O’Keeffe 1996; Reades 2011; Slesak 2003; Spandorfer 2005), and for the infusion of medication (including insulin, bone marrow, immunoglobulin and bleomycin) in six trials (Boullu-Sanchis 2006; Hägglund 1998; Harbo 2009; Harvey 1987; Liebl 2009; Selam 1983).

Interventions
The included trials compared the following:
- Intravenous access versus intracutaneous access, four trials (Banerjee 1994; Hägglund 1998; Lamhaut 2010 (no PPE); Lamhaut 2010 (with PPE); Reades 2011).
- Intravenous access versus intraperitoneal access, one trial (Selam 1983).
- Saphenous vein cutdown versus intracutaneous access, one trial (Hubble 2001).
- Intraperitoneal access versus subcutaneous access, one trial (Selam 1983).

All of the trials assessing the intravenous method involved peripheral intravenous access. One cross-over trial by Lamhaut et al compared intravenous and intracutaneous insertion with and without the wearing of PPE. For the purpose of the meta-analysis, we considered separately the data for the comparison of intravenous and intracutaneous insertion without PPE (Lamhaut 2010 (no PPE)) and with PPE (Lamhaut 2010 (with PPE)).

The trial by Reades et al compared intravenous access with two intracutaneous groups; one involved insertion into the humerus and the other into the tibia (Reades 2011). For the purpose of the meta-analysis, we combined the data from the two intracutaneous groups to derive a single comparison with the intravenous group. The cross-over trial by Selam et al compared three parenteral methods for administering insulin - intravenous, subcutaneous and intraperitoneal (Selam 1983). We considered separately the results from the three single pair-wise comparisons (intravenous versus subcutaneous, intravenous versus intraperitoneal, and subcutaneous versus intraperitoneal) in this review.

Outcomes
The trials reporting data on the outcomes of interest are as follows:
• Success of route of insertion, six trials.
• Time to infusion/placement, four trials.
• Number of insertion attempts, one trial.
• Dislodgement of device during infusion, two trials.
• Time period with functional access, one trial.
• Local site reactions (e.g. erythema, oedema, swelling, infection), 11 trials.
• Clinician’s perception of ease of administration, three trials.
• Needlestick injury to healthcare workers; no trials.
• Patient’s discomfort (pain or discomfort); five trials.
• Mortality, two trials.
• Volume of fluid infused, five trials.
• Serum sodium, two trials.

• Serum potassium, one trial.
• Urea, two trials.
• Creatinine, three trials.

Excluded studies
A list of excluded studies with the reasons for their exclusion is presented in Characteristics of excluded studies.

Risk of bias in included studies
Our judgements regarding each ‘Risk of bias’ item for each included trial are presented in Figure 2.
Figure 2. 'Risk of bias' summary: review authors’ judgements about each risk of bias item for each included study.

<table>
<thead>
<tr>
<th>Study</th>
<th>Random sequence generation (selection bias)</th>
<th>Allocation concealment (selection bias)</th>
<th>Binding of outcome data (detection bias)</th>
<th>Outcomes related to potential role (performance bias)</th>
<th>Blinding of outcome assessment (detection bias)</th>
<th>Selective reporting (reporting bias)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danquah 1994</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Routh-Banich 2006</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Chaffin 1994</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Dardaine 1995</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Dabatens 1992</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Duerr 1997</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Hågström 1996</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Harbo 2009</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Hansley 1967</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Habble 2001</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Lamhaut 2010 (no PPE)</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Lamhaut 2010 (with PPE)</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Liab 2009</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>O’Keeffe 1996</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Reades 2011</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Saudam 1983</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Siesalk 2003</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Sparr 2005</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
</tbody>
</table>

Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease (Review)

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Allocation

Sequence generation
One trial alternately assigned patients into groups and we judged it to be at high risk of bias (Banerjee 1994). Four trials used an adequate method of sequence generation and we judged them to be at low risk of bias; of these, one trial referred to a random numbers table (O'Keeffe 1996), and three used computer-generated randomisation (Challiner 1994; Lamhaut 2010 (no PPE); Lamhaut 2010 (with PPE); Spandorfer 2005). We rated the remaining 12 trials as unclear due to insufficient information (Boullu-Sanchis 2006; Dardaine 1995; Delamaire 1992; Duems Noriega 2014; Hägglund 1998; Harbo 2009; Harvey 1987; Hubble 2001; Liebl 2009; Reades 2011; Selam 1983; Slesak 2003).

Allocation concealment
We judged allocation to have been inadequately concealed and at high risk of bias in two trials (Banerjee 1994; Reades 2011). Two trials used a method of central allocation (Harbo 2009; Spandorfer 2005), and one trial used sequentially numbered, sealed envelopes (Challiner 1994); we considered all three to be adequately concealed and at low risk of bias. We rated the remaining 12 trials as unclear due to insufficient information (Boullu-Sanchis 2006; Dardaine 1995; Delamaire 1992; Duems Noriega 2014; Hägglund 1998; Harvey 1987; Hubble 2001; Lamhaut 2010 (no PPE); Lamhaut 2010 (with PPE); Liebl 2009; O'Keeffe 1996; Selam 1983; Slesak 2003).

Blinding

Blinding of participants and personnel
Due to the nature of the interventions under study, it was not feasible for participants and personnel to be blinded to allocation status and we judged all 17 trials to be at high risk of bias, although it is unclear in which direction the results would have been biased.

Blinding of outcome assessment

Outcomes related to parenteral route insertion
We judged that measurement of these outcomes was likely to have been influenced by lack of blinding so we judged all 10 trials reporting data on these outcomes to be at high risk of bias (Banerjee 1994; Challiner 1994; Spandorfer 2005).

Clinical outcomes
We judged that measurement of these outcomes was likely to have been influenced by lack of blinding so we judged all four trials reporting data on these outcomes to be at low risk of bias (Banerjee 1994; Challiner 1994; Duems Noriega 2014; Slesak 2003).

Subjective outcomes
We judged that measurement of these outcomes was likely to have been influenced by lack of blinding so we judged all 13 trials reporting data on these outcomes to be at high risk of bias (Banerjee 1994; Challiner 1994; Duems Noriega 2014; Slesak 2003).

Incomplete outcome data

Outcomes related to parenteral route insertion
Of the 11 trials reporting data on one or more of these outcomes, we judged three to be at high risk of bias (Banerjee 1994; Challiner 1994; Duems Noriega 2014), and eight to be at low risk of bias (Dardaine 1995; Delamaire 1992; Hubble 2001; Lamhaut 2010 (no PPE); Lamhaut 2010 (with PPE); Reades 2011; Selam 1983; Slesak 2003; Spandorfer 2005).

Clinical outcomes
Of the six trials reporting data on one or more of these outcomes, we judged three to be at high risk of bias (Banerjee 1994; Duems Noriega 2014; O'Keeffe 1996), and three at low risk of bias (Challiner 1994; Reades 2011; Slesak 2003).

Subjective outcomes
Of the 13 trials reporting data on one or more of these outcomes, we judged four to be at high risk of bias (Duems Noriega 2014; Hägglund 1998; Liebl 2009; O'Keeffe 1996), and nine at low risk of bias (Boullu-Sanchis 2006; Challiner 1994; Delamaire 1992; Harbo 2009; Hubble 2001; Reades 2011; Selam 1983; Slesak 2003; Spandorfer 2005).
Selective reporting
We found clinical trial registration records for two trials, both of which had been registered after the start of recruitment. For one of these trials, outcomes not mentioned in the registration record were reported within the final report so we judged this trial to be at high risk of bias (Reades 2011). There were no apparent differences in the specified outcomes for the second trial, which we judged to be at unclear risk of bias due to the retrospective registration (Harbo 2009). We also judged the risk of bias for the remaining 15 trials to be unclear as we had insufficient information to permit judgement.

Effects of interventions
See: Summary of findings for the main comparison Intravenous versus intraosseous route for achieving parenteral access; Summary of findings 2 Intravenous versus subcutaneous route for achieving parenteral access; Summary of findings 3 Saphenous vein cutdown versus intraosseous route for achieving parenteral access

Peripheral intravenous versus intraosseous access
We have presented separately two effect estimates from one four-period cross-over trial in the analyses but have not combined these with data from parallel-group trials (Lamhaut 2010 (no PPE); Lamhaut 2010 (with PPE)).

Insertion failures
Insertion failures were reported by three trials (Banerjee 1994; Lamhaut 2010 (no PPE); Lamhaut 2010 (with PPE); Reades 2011). The data from Lamhaut 2010 (no PPE) and Lamhaut 2010 (with PPE) originated from the same cross-over trial, therefore we did not pool these data in the meta-analysis. Furthermore, as there were no failures in either Lamhaut 2010 (no PPE) or Lamhaut 2010 (with PPE) treatment effects for these comparisons could not be estimated. The pooled estimate is therefore based on data from Banerjee 1994 and Reades 2011. More patients in the intravenous group experienced an insertion failure than in the intraosseous group (risk ratio (RR) 3.89, 95% confidence interval (CI) 2.39 to 6.33; n = 242; P value < 0.0001) (Analysis 1.1). There was moderate statistical heterogeneity between trials (I² = 48%), however it was not statistically significant (Chi² P value = 0.16) and the direction of the effect estimates was consistent. We rated the quality of the evidence as low according to GRADE, as we downgraded it for risk of bias and imprecision (Summary of findings for the main comparison).

Subgroup analysis
There was no evidence of a difference in effect according to the age of participants. The risk of insertion failure was higher in the intravenous group in both the one trial involving adults (RR 3.24, 95% CI 2.00 to 5.27; n = 182; P value < 0.0001) (Reades 2011), and the one trial involving children (RR 21.00, 95% CI 1.29 to 342.93; n = 60; P value = 0.03) (Banerjee 1994) (test for subgroup differences: Chi² = 1.67, df = 1 (P value = 0.20), I² = 40.1%).

Time to infusion/placement
Time to infusion/placement was reported by three trials (Banerjee 1994; Lamhaut 2010 (no PPE); Lamhaut 2010 (with PPE); Reades 2011). Due to clinical heterogeneity we did not calculate a pooled estimate, although effect estimates from each trial are presented on a forest plot to provide a visual summary. It took longer to achieve intravenous access than intraosseous access in all trials, with the difference reaching statistical significance in two trials but not in the third (Analysis 1.3). In Reades 2011, the data for the humerus intraosseous and tibia intraosseous groups were combined for the analysis, although we note that there was a difference in the average time taken for insertion between the sites: mean ± standard deviation (SD) for humeral insertion = 420 seconds ± 91.50 and for tibial insertion = 276 seconds ± 39.75.

We rated the quality of the evidence as moderate according to GRADE, as we downgraded it for risk of bias (Summary of findings for the main comparison).

Average number of insertion attempts
The average number of insertion attempts was reported by one trial (Reades 2011). There was no difference between the two groups (mean difference (MD) 0.00, 95% CI -0.07 to 0.07; n = 182; P value = 1.00) (Analysis 1.4).

Dislodgement of device during infusion
Dislodgement of the device during infusion was reported by one trial (Reades 2011). There were fewer dislodgements in the intravenous access group, although the difference is not statistically significant (RR 0.53, 95% CI 0.18 to 1.55; n = 182; P value = 0.25) (Analysis 1.5). Most of the dislodgements (10/13) occurred in the intraosseous patients who had the device inserted into the proximal humerus.

We rated the quality of the evidence as low according to GRADE, as we downgraded it for risk of bias and imprecision (Summary of findings for the main comparison).

Time with functional access
None of the trials reported data on this outcome.
Local site reactions

Infection

One trial, involving the infusion of bone marrow, reported number of patients who developed bacteraemia during the first month (Hägglund 1998). There were fewer cases of bacteraemia in the intravenous group, although the difference was not statistically significant (RR 5.57, 95% CI 0.35 to 88.77; n = 28; P value = 0.22) (Analysis 1.6).

Clinician's perception of administration of access route

One trial measured the paramedics' perception of how comfortable they felt when administering each method to each patient (Reades 2011). Paramedics were less likely to report that they were uncomfortable when inserting via the intravenous route (RR 0.15, 95% CI 0.04 to 0.61; n = 182; P value = 0.008) (Analysis 1.7).

Needlestick injuries

None of the trials reported data on this outcome.

Patient discomfort

None of the trials reported data on this outcome.

Mortality

None of the trials reported data on this outcome.

Volume of fluid infused

The volume of fluid infused was reported by one trial (Reades 2011). A larger volume of fluid was infused via the intravenous route than the intraosseous route (MD 400 ml, 95% CI 365.57 to 434.43; n = 182; P value < 0.0001) (Analysis 1.8). We rated the quality of the evidence as moderate according to GRADE, as we downgraded it for risk of bias (Summary of findings for the main comparison).

Electrolyte level

Electrolyte level was reported by one trial (Banerjee 1994). There was no evidence of a difference in serum sodium (MD -1.00, 95% CI -5.36 to 3.36; n = 60; P value = 0.65) or potassium (MD -0.40, 95% CI -2.97 to 2.17; n = 60; P value = 0.76) between groups (Analysis 1.9).

Renal function

Renal function was reported by one trial (Banerjee 1994). The average levels of both urea and creatinine were lower in the intravenous group; the difference was not statistically significant for urea (MD -5.00, 95% CI -10.53 to 0.53; n = 60; P value = 0.08), but it was statistically significant for creatinine (MD -35.00, 95% CI -44.66 to -25.34; n = 60; P value < 0.0001) (Analysis 1.10).

Sensitivity analysis

Sensitivity analysis was not possible as we judged none of the trials comparing intravenous and intraosseous access to be at low risk of bias for allocation concealment.

Peripheral intravenous versus subcutaneous access

Insertion failures

Insertion failures were reported by three trials (Delamaire 1992; O’Keeffe 1996; Spandorfer 2005). More patients in the intravenous group experienced an insertion failure than in the subcutaneous group (RR 14.79, 95% CI 2.87 to 76.08; n = 238) (Analysis 2.1). There was no statistical heterogeneity between trials (Chi² P value = 0.50; I² = 0%). We rated the quality of the evidence as moderate according to the GRADE system, as we downgraded it for imprecision (Summary of findings 2).

Sensitivity analysis

The effect remained when we restricted the analysis to the one trial with adequate allocation concealment (Spandorfer 2005) (RR 32.13, 95% CI 1.96 to 525.87; n = 148; P value = 0.01) (Analysis 2.2).

Subgroup analysis

Two trials involved adults (Delamaire 1992; O’Keeffe 1996), and one trial involved children (Spandorfer 2005). The effect estimates for both subgroups were consistent, with an increased risk of insertion failures in the intravenous group, although the effect was not statistically significant for the subgroup of trials involving adults (adults RR 6.00, 95% CI 0.76 to 47.39; n = 90; P value = 0.09 versus children RR 32.13, 95% CI 1.96 to 525.87; n = 148; P value = 0.01). However, there is no evidence that the effect varied between these subgroups (test for subgroup differences: Chi² = 0.90, df = 1 (P value = 0.34), I² = 0%).
Time to infusion/placement

Time to placement/start of infusion was reported by two trials (Slesak 2003; Spandorfer 2005). Insertion of the intravenous route took longer than the subcutaneous route in both trials, however a pooled estimate could not be calculated because of insufficient data (i.e. no variance estimates) presented in Spandorfer 2005. In Slesak 2003, it took on average two minutes longer (MD 120.00 seconds, 95% CI -4.80 to 244.80; n = 96; P value = 0.06) to insert via the intravenous route (Analysis 2.4). In Spandorfer 2005 (n = 148), the median time from first insertion attempt to start of infusion in the intravenous group was 11.8 minutes compared to 3.5 minutes in the subcutaneous group.

We rated the quality of the evidence as low according to GRADE, as we downgraded it for risk of bias and imprecision (Summary of findings 2).

Average number of insertion attempts

The average number of insertion attempts was not directly measured by any of the trials. However, O’Keeffe 1996 (n = 60) reported that 41 cannulae were used in the intravenous group compared to 34 in the subcutaneous group.

Dislodgement of device during infusion

One trial reported the number of dislodgements caused by patients pulling out the device (Duems Noriega 2014). Patients in the intravenous group were more likely to dislodge the device than those in the subcutaneous group (RR 3.78, 95% CI 1.16 to 12.34; n = 67; P value = 0.03) (Analysis 2.5).

We rated the quality of the evidence as low according to GRADE, as we downgraded it for risk of bias and imprecision (Summary of findings 2).

Time with functional access

One trial measured the length of time in days before each cannula needed to be changed (Slesak 2003). There was no statistically significant difference observed between groups (MD 0.80 days, 95% CI -0.05 to 1.65; n = 96; P value = 0.07) (Analysis 2.6).

Local site reactions

See Analysis 2.7 and Analysis 2.8.

Any

The occurrence of any local site reactions was reported by five trials (Boullu-Sanchis 2006; Challiner 1994; Harbo 2009; Selam 1983; Spandorfer 2005). There were fewer local site reactions in the intravenous group than in the subcutaneous group, although the difference was not statistically significant (RR 0.91, 95% CI 0.80 to 1.02; n = 247). There was substantial statistical heterogeneity between trials (Chi² P value < 0.0001; I² = 58%).

Sensitivity analysis

There was a statistically significant reduced risk associated with the intravenous method when the analysis was restricted to the three trials with adequate allocation concealment (Challiner 1994; Harbo 2009; Spandorfer 2005) (RR 0.87, 95% CI 0.79 to 0.96; n = 202). There was no evidence of statistical heterogeneity between trials (Chi² P value = 0.30; I² = 17%).

Erythema

Erythema was reported by four trials (Challiner 1994; Harbo 2009; Slesak 2003; Spandorfer 2005). There were fewer cases of erythema in the intravenous group than in the subcutaneous group (RR 0.43, 95% CI 0.31 to 0.61; n = 296). There was substantial statistical heterogeneity between trials (Chi² P value < 0.0001; I² = 63%).

Sensitivity analysis

The effect remained when we restricted the analysis to the three trials with adequate allocation concealment (Challiner 1994; Harbo 2009; Spandorfer 2005) (RR 0.33, 95% CI 0.22 to 0.49; n = 202). There was no statistical heterogeneity between trials (Chi² P value = 0.73; I² = 0%).

Swelling

Swelling was reported by one trial (Spandorfer 2005). There were fewer cases of swelling in the intravenous group than in the subcutaneous group (RR 0.26, 95% CI 0.17 to 0.41; n = 148).

Infection

Infection was reported by four trials (Delamaire 1992; Duems Noriega 2014; Harbo 2009; Slesak 2003). More patients in the intravenous group developed an infection (e.g. cellulitis and lymphangitis) compared to the subcutaneous group (RR 3.70, 95% CI 1.06 to 12.88; n = 211; P value = 0.04). There was no statistical heterogeneity between trials (Chi² P value = 0.37; I² = 6%).

Sensitivity analysis

There was no difference in the risk of infection between groups when we restricted the analysis to the one trial with adequate allocation concealment (Harbo 2009) (RR 3.00, 95% CI 0.14 to 65.16; n = 18; P value = 0.48).
Oedema

Oedema was reported by seven trials (Challiner 1994; Delamaire 1992; Duems Noriega 2014; Harbo 2009; O’Keeffe 1996; Slesak 2003; Spandorfer 2005). Fewer patients in the intravenous group experienced oedema at the insertion site compared to those in the subcutaneous group (RR 0.42, 95% CI 0.25 to 0.72; n = 453; P value = 0.001). There was no statistical heterogeneity between trials (Chi² P value = 0.89; I² = 0%).

**Sensitivity analysis**

The effect was not statistically significant when we restricted the analysis to the three trials with adequate allocation concealment (Challiner 1994; Harbo 2009; Spandorfer 2005) (RR 0.25, 95% CI 0.06 to 1.15; n = 202; P value = 0.07). There was no statistical heterogeneity between trials (Chi² P value = 0.93; I² = 0%).

Phlebitis

Phlebitis was reported by three trials (Duems Noriega 2014; Harbo 2009; Slesak 2003). More patients in the intravenous group experienced phlebitis than in the subcutaneous group (RR 5.04, 95% CI 1.14 to 22.30; n = 181). There was no statistical heterogeneity between trials (Chi² P value = 0.93; I² = 0%).

**Sensitivity analysis**

The effect was not statistically significant when we restricted the analysis to the one trial with adequate allocation concealment (Harbo 2009) (RR 3.00, 95% CI 0.14 to 65.16; n = 18; P value = 0.48).

Clinician’s perception of ease of administration

Slesak 2003 measured doctors’ and nurses’ perceptions of the feasibility of each insertion method using a Likert-like scale. There was no difference between the perceived feasibility of the two methods when scored by either the nurses (MD 0.00, 95% CI -0.12 to 0.12; n = 87; P value = 1.00) or doctors (MD 0.00, 95% CI -0.14 to 0.14; n = 96; P value = 1.00) (Analysis 2.9).

In Spandorfer 2005, clinicians were more likely to report that the intravenous access was difficult to perform than the subcutaneous access (RR 6.33, 95% CI 2.32 to 17.23; n = 148; P value = 0.0003) (Analysis 2.10).

Needlestick injuries

None of the trials reported data on this outcome.

Patient discomfort

Pain

Three trials reported the number of patients with pain associated with the parenteral access method (Harbo 2009; Slesak 2003; Spandorfer 2005). There is no evidence that the number of patients reporting pain differed between the intravenous and subcutaneous groups (RR 1.01, 95% CI 0.83 to 1.22; n = 262; P value = 0.94). There was no statistical heterogeneity between trials (Chi² P value = 0.94; I² = 0%) (Analysis 2.11). We downgraded the quality of the evidence to low, due to high risk of bias and imprecision arising from small sample sizes.

**Sensitivity analysis**

The lack of evidence for a difference remained when we restricted the analysis to the two trials with adequate allocation concealment (Harbo 2009; Spandorfer 2005) (RR 0.97, 95% CI 0.81 to 1.16; n = 166; P value = 0.77). There was evidence of statistical heterogeneity between trials (I² = 53%); however, it was not statistically significant (Chi² P value = 0.15) (Analysis 2.12).

Discomfort

In Slesak 2003, patients were also asked to score the discomfort of the procedure (1 = very good to 6 = very bad). There was no difference in the patients’ scores between the two groups (MD 0.00, 95% CI -0.21 to 0.21; n = 54; P value = 1.00) (Analysis 2.13).

Agitation

Two trials reported the number of patients who were agitated (Duems Noriega 2014; O’Keeffe 1996). Patients in the intravenous group were more likely to be agitated than those in the subcutaneous group (RR 1.84, 95% CI 1.26 to 2.70; n = 125; P value = 0.002). There was no statistical heterogeneity between trials (Chi² P value = 0.34; I² = 0%).

Mortality

Mortality was reported by two trials (Challiner 1994; Duems Noriega 2014). In Challiner 1994, one patient in the subcutaneous group died on day two and in Duems Noriega 2014, three patients (two in the intravenous group, one in the subcutaneous group) died in the first 72 hours. When we pooled the data there was no difference in the risk of death between groups (RR 1.04, 95% CI 0.18 to 5.92; n = 103; P value = 0.96). There was no statistical heterogeneity between trials (Chi² P value = 0.40; I² = 0%) (Analysis 2.14).
**Sensitivity analysis**
The lack of evidence for a difference in risk remained when we restricted the analysis to the one trial with adequate allocation concealment (Challiner 1994) (RR 0.37, 95% CI 0.02 to 8.53; n = 36; P value = 0.53) (Analysis 2.15).

**Volume of fluid infused**
The volume of fluid infused was reported by four trials (Duems Noriega 2014; O’Keeffe 1996; Slesak 2003; Spandorfer 2005). Due to clinical heterogeneity we did not calculate a pooled estimate, although effect estimates from each trial are presented on a forest plot to provide a visual summary (Analysis 2.16). A larger volume of fluid was infused via the intravenous route in all but one trial. We rated the quality of the evidence as low according to GRADE, as we downgraded it for risk of bias and inconsistency (Summary of findings 2).

**Sensitivity analysis**
There was no difference in the volume of fluid infused in the one trial with adequate allocation concealment (Spandorfer 2005) (MD 90.80 95% CI -63.55 to 245.15; n = 148; P value = 0.25).

**Electrolyte levels**

**Sodium**
Sodium level was reported by one trial (Slesak 2003). The mean sodium level was higher in the intravenous group (139 ± 5 mmol/l) compared to the subcutaneous group (137 ± 5 mmol/l), although the difference is not statistically significant (MD -2.00 mmol/l, 95% CI -0.24 to 4.24; n = 77; P value = 0.08) (Analysis 2.18).

**Potassium**
None of the trials reported data on this outcome.

**Renal function**
See Analysis 2.19.

**Urea**
Urea level was reported by one trial (Duems Noriega 2014). Urea levels were on average lower in the intravenous group than in the subcutaneous group, although the difference is not statistically significant (MD -11.29 mg/dL, 95% CI -24.69 to 2.11; n = 67; P value = 0.10).

**Creatinine**
Creatinine level was reported by two trials (Duems Noriega 2014; Slesak 2003). There was no difference in creatinine levels between the two groups (MD -0.08, 95% CI -0.33 to 0.16; n = 138; P value = 0.51). There was no statistical heterogeneity between trials (Chi² P value = 0.95; I² = 0%).

**Saphenous vein cutdown versus intraosseous access**
This comparison was assessed by one cross-over trial (n = 13) (Hubble 2001).

**Insertion failures**
There were more failures when attempting saphenous vein cutdown than intraosseous access, although the difference was not statistically significant (RR 4.00, 95% CI 0.51 to 31.13; P value = 0.19) (Analysis 3.1). We rated the quality of the evidence as low according to GRADE, as we downgraded it for risk of bias and imprecision (Summary of findings 3).

**Time to infusion/placement**
On average it took about 3.5 minutes longer to achieve access by saphenous vein cutdown than intraosseous access (MD 219.60 seconds, 95% CI 135.44 to 303.76; P value < 0.0001) (Analysis 3.2). We rated the quality of the evidence as moderate according to GRADE, as we downgraded it for risk of bias (Summary of findings 3).

**Average number of insertion attempts**
The trial did not report data on this outcome.

**Dislodgement of device during infusion**
The trial did not report data on this outcome.

**Time with functional access**
This outcome was not relevant, as insertion attempts were on a cadaver.

**Local site reactions**
This outcome was not relevant, as both insertion attempts were on a cadaver.
The trial did not report data on this outcome.

The trial did not report data on this outcome.

This outcome was not relevant, as insertion attempts were on a cadaver.

This outcome was not relevant, as insertion attempts were on a cadaver.

This outcome was not relevant, as both trials involved the infusion of medication, not fluids for hydration.

This outcome was not relevant, as both trials involved the infusion of medication, not fluids for hydration.

Two cross-over trials compared the intraperitoneal and subcutaneous routes for infusion of medications (Liebl 2009; Selam 1983).

Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
**Insertion failures**  
The trials did not report data on this outcome.

**Time to infusion/placement**  
The trials did not report data on this outcome.

**Average number of insertion attempts**  
The trials did not report data on this outcome.

**Dislodgement of device during infusion**  
The trials did not report data on this outcome.

**Time with functional access**  
The trials did not report data on this outcome.

**Local site reactions**  
In Selam 1983, all six patients experienced local reactions after three to four weeks of the subcutaneous phase, beginning with induration and inflammation at the insertion site before rejection of the catheter.  
In Liebl 2009, it is reported that 21% of patients in months one to six and 10% patients in months seven to 12 experienced local inflammation or infection during the intraperitoneal phase. The number of complications during the subcutaneous phase was not reported.

**Clinician’s perception of ease of administration**  
The trials did not report data on this outcome.

**Needlestick injuries**  
The trials did not report data on this outcome.

**Patient discomfort**  
In Selam 1983, two of the six patients suffered transient episodes of abdominal pain during the intraperitoneal phase.  
In Liebl 2009, it is reported that 12% of patients in months one to six and 49% in months seven to 12 reported severe pain during the intraperitoneal phase.

**Mortality**  
The trials did not report data on this outcome.

**Volume of fluid infused**  
The outcome was not relevant, as both trials involved the infusion of medication not fluids for hydration.

**Electrolyte levels**  
The outcome was not relevant, as both trials involved the infusion of medication not fluids for hydration.

**Renal function**  
The outcome was not relevant, as both trials involved the infusion of medication not fluids for hydration.

**Reporting bias**  
There were insufficient data to produce funnel plots for any of the outcomes.
### ADDITIONAL SUMMARY OF FINDINGS

**Intravenous versus subcutaneous route for achieving parenteral access**

**Patient or population:** adults or children requiring parenteral access for infusion of fluids or medication  
**Settings:** USA (children’s unit) and Europe (older people care units)  
**Intervention:** intravenous route  
**Comparison:** subcutaneous route

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative risks* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No of participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Assumed risk</td>
<td>Corresponding risk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subcutaneous route</td>
<td>Study population</td>
<td>RR 14.79 (2.87 to 76.08)</td>
<td>238</td>
<td>⊕⊕⊕</td>
<td>MODERATE 1,2</td>
</tr>
<tr>
<td></td>
<td>There were no insertion failures observed with the subcutaneous route in the studies</td>
<td></td>
<td></td>
<td></td>
<td>IV rate calculated based on an assumed rate with the subcutaneous route generated from correction for zero events (1.14 per 100)</td>
</tr>
<tr>
<td></td>
<td>Time to infusion/placement</td>
<td>The mean time to placement/start of infusion in the IV group was 120 seconds longer (4.8 shorter to 244.8 longer)</td>
<td>-</td>
<td>⊕⊕</td>
<td>LOW 3,4</td>
</tr>
<tr>
<td></td>
<td>Dislodgement of device</td>
<td>RR 3.78 (1.16 to 12.34)</td>
<td>67</td>
<td>⊕⊕</td>
<td>LOW 3,4</td>
</tr>
<tr>
<td>Needlestick injuries</td>
<td>No studies reported this outcome</td>
<td>No studies reported this outcome</td>
<td>-</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>
Volume of fluid infused

There was variation in the amount of fluid administered between trials, therefore we did not pool data. The size and direction of the effects differed across the 4 studies reporting data for this outcome

(4 RCTs)

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

1 Downgraded one level for imprecision: estimate is statistically significant at the 5% level (P value <0.001); however, the estimated required information size has not been achieved and we cannot discount the possibility that it is a false positive. Downgraded one level for risk of bias: estimates based on trials at unclear and/or high risk of bias for > 1 domain.

2 Not downgraded for risk of bias as effect remained when analysis was restricted to adequately concealed trials.

3 Downgraded one level for risk of bias: estimate based on trial(s) at unclear and/or high risk of bias for ≥ 1 domain.

4 Downgraded one level for inconsistency: effect borderline or not statistically significant at the 5% level and/or wide CI.

5 Downgraded one level for inconsistency: variation in both magnitude (I^2 > 50%) and direction of effects.

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; IV: intravenous; NA: not applicable; RCT: randomised controlled trial; RR: risk ratio
Saphenous vein cutdown versus intraosseous route for achieving parenteral access

**Patient or population:** trainee paramedics using both methods of gaining parenteral access on cadavers  
**Settings:** USA (training laboratory)  
**Intervention:** saphenous vein cutdown  
**Comparison:** intraosseous

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative risks* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No of participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Assumed risk</td>
<td>Corresponding risk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Intraosseous</td>
<td>Saphenous vein cutdown</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insertion failures</td>
<td>Study population</td>
<td>RR 4 (0.51 to 31.13)</td>
<td>13 (1 RCT)</td>
<td>Ⓝ⃝⃣ LOW⃝⃣⃣</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>77 per 1000</td>
<td>308 per 1000 (39 to 2395)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time to infusion/placement</td>
<td>Analysed as generic inverse variance outcome type. Difference between means was 219.6 seconds longer with saphenous vein cutdown (155.09 longer to 284.11 longer)</td>
<td>-</td>
<td>13 (1 RCT)</td>
<td>Ⓝ⃝⃝ MODERATE</td>
<td>-</td>
</tr>
<tr>
<td>Dislodgement of device</td>
<td>No studies reported this outcome</td>
<td>-</td>
<td>NA</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Needleskirt injuries</td>
<td>No studies reported this outcome</td>
<td>-</td>
<td>NA</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Volume of fluid inserted</td>
<td>No studies reported this outcome</td>
<td>-</td>
<td>NA</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>
The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; NA: not applicable; RCT: randomised controlled trial; RR: risk ratio

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

1 Downgraded one level due to risk of bias: estimate based on trial at high or unclear risk of bias for all domains.

2 Downgraded one level for imprecision: estimate based on few events and wide CI that includes both appreciable increase and decrease in risk.
**DISCUSSION**

**Summary of main results**

Evidence from randomised controlled trials suggests that intraosseous access may be achieved more rapidly and with fewer insertion failures than intravenous access. Subcutaneous access is also associated with fewer insertion failures than intravenous access. Taken together the evidence suggests that intraosseous and subcutaneous access are viable alternatives to peripheral intravenous access when the latter cannot be achieved. However, when inserted successfully, more fluid can be infused by the intravenous route than by either the intraosseous or subcutaneous route.

Only one small trial involving insertion of parenteral access into manikins explored the effect of personal protective equipment (PPE), thus there is insufficient evidence to determine reliably whether or not the use of PPE impacts on the merits of the different approaches. Also, there is insufficient evidence to draw any inferences about the relative merits of intraosseous access compared to other methods and there are no trials involving central intravenous access.

A particularly important consideration in the context of patients with Ebola virus disease (EVD) may be the likelihood of dislodgement of the parenteral access device during use. Two trials, one comparing intravenous with intraosseous access and one comparing intravenous with subcutaneous access, recorded the number of dislodgements. However, both were inadequately powered and were at risk of bias for important quality domains. They therefore do not provide reliable evidence on this important outcome so we are unable to draw any firm conclusions. There are also insufficient data to determine whether the intravenous route is associated with an increased or decreased risk of adverse events when compared to intraosseous access. When compared to subcutaneous access, intravenous access appears to cause less erythema, but more infection and phlebitis. However, the difference between the two methods in the risk of infection and phlebitis was not statistically significant when we restricted these analyses to trials with adequate allocation concealment. As expected given the nature of the insertion, subcutaneous infusion was associated with an increased risk of oedema and swelling.

**Quality of the evidence**

We judged few trials to be at low risk of bias for any of the assessed domains. Of particular concern is the small number of trials (n = 3) that used adequate allocation concealment. Where possible we explored the influence of trials with unclear or high risk of bias for allocation concealment using sensitivity analyses. Blinding was not feasible due to the nature of the interventions and this may have introduced bias, particularly in the assessment of subjective outcomes. In some trials, attrition between groups might also have introduced bias. For example, in Banerjee 1994 10 patients (30%) allocated to the intravenous group were switched to the intravenous group because venous access could not be achieved. It is possible that these patients were more dehydrated, which might account for the difficulty with venous access. As the trial data were not presented on an intention-to-treat basis, a favourable effect of intraosseous access on outcomes may have been diluted. Also, because the estimated information size for the meta-analysis (n = 1388) was not achieved for the primary outcome (insertion failures) for any of the routes compared, we cannot discount the possibility that the observed increase in risk of insertion failure associated with the intravenous method compared to both the intraosseous and subcutaneous methods is false positives, although the P values accompanying the pooled effect estimates are very small (≤ 0.001).
**Potential biases in the review process**

As with all systematic reviews, publication and reporting biases should be considered as potential threats to the validity of the findings of this review. We undertook comprehensive searching but cannot discount the possibility that trials, in particular unpublished trials, were not identified.

Also, few trials contributed data to each outcome, which may suggest some selective outcome reporting. Indeed, comparison of prespecified outcomes with those given in the final report for the one trial that was prospectively registered, did suggest selective outcome reporting. However, this could not be explored for the other included trials, which had not been prospectively registered. We were also unable to explore the presence of reporting bias using funnel plots because there were too few trials included in the meta-analyses.

Two trials reported data for some continuous outcomes as medians and ranges (Reades 2011; Slesak 2003). To allow these data to be included in the meta-analyses, we estimated the corresponding means and standard deviations using the approach described in Hozo 2005. However, meta-analysis of the difference in means is appropriate, assuming that the data are normally distributed. That these data were presented as medians and ranges may indicate that their distributions were skewed and not normally distributed. The estimates of the mean difference based on these data should therefore be interpreted with caution.

**Agreements and disagreements with other studies or reviews**

The findings of this systematic review are largely consistent with those of other relevant literature reviews. We identified two other reviews that summarised the results of observational and intervention studies assessing the use of subcutaneous infusion for treating dehydration in older adults (Remington 2007; Rochon 1997). The conclusion of both reviews was that subcutaneous infusion is a safe and feasible alternative to intravenous fluid administration for treating mild to moderate dehydration in the elderly.

Another article reported the results of a systematic review of observational and intervention studies assessing the effectiveness of non-oral and non-intravenous methods for treating dehydration in children (Rouhani 2011). The authors noted the lack and limited quality of the evidence, but concluded that the intravenous method could be an effective alternative when intravenous access is not feasible. Although they noted promising results from case series studies, they also concluded that there was insufficient evidence to recommend the intraperitoneal or subcutaneous method above other parenteral access methods in this patient group.

**Authors’ conclusions**

**Implications for practice**

There are several different ways of achieving parenteral access in patients who are unable to meet their fluid requirements enterally. In view of the large number of cases and the severe resource constraints, methods for achieving parenteral access in the context of Ebola virus disease (EVD) need to be simple, easy and quick, and must not put healthcare workers at unnecessary risk. The quality of the evidence in this review is somewhat limited, largely because of the lack of adequately powered trials at low risk of bias. Although this prevents us from drawing firm conclusions regarding the magnitude of the difference between parenteral access methods, useful inferences about the likely direction of effects can be made for some outcomes.

The choice of method used in clinical practice may depend on site-specific issues such as the availability and expertise of medical and nursing staff, patient numbers and local infrastructure. If intravenous access can be achieved easily, this facilitates the infusion of larger volumes of fluid and also allows blood samples to be drawn for testing (e.g. for EVD or malaria) at the time of insertion. However, if this is not possible, intravenous access can be achieved rapidly. The subcutaneous route may be suitable for patients who are not severely dehydrated but in whom ongoing fluid losses cannot be met by oral intake. Given the ease of insertion of subcutaneous lines, they could be inserted by healthcare workers with minimal medical training.

It is expected that most clinicians are familiar with the intravenous method, but may be less so with the other methods although these can be easily taught.

A film to accompany this review can be viewed here.

**Implications for research**

The quality of the included trials was low. Further comparative trials of alternative approaches are appropriate if those caring for patients with EVD remain uncertain about which is the most effective strategy for securing reliable parenteral access. Importantly, there is no reliable information on the extent to which the different parenteral access devices are dislodged during use. This might be particularly relevant in the context of the current epidemic of EVD, where there are shortages of nursing and medical staff, since the volume of fluid administered might depend on the duration of parenteral access. Also, there is a lack of data on the impact of personal protective equipment on parenteral access methods and whether effects differ in children, which should be addressed by future trials. There are no data on the relative merits of intraperitoneal access. This method has been used to resuscitate severely dehydrated infants with cholera in whom achieving intravenous access is difficult (Mahalanabis 1970). Whether it is more effective than intravenous, intramuscular or subcutaneous access remains unknown. Future trials should be prospectively registered, have
secure allocation concealment, adequate sample sizes and should be reported according to established standards.

ACKNOWLEDGEMENTS

We are grateful for feedback from the anonymous peer referees. We acknowledge the support and assistance from the Cochrane Editorial Unit, especially Toby Lasserson. We also thank Monica Arribas and Emma Sydenham for help with the translation of non-English language articles.

REFERENCES

References to studies included in this review

Banerjee 1994 [published data only]

Boullu-Sanchis 2006 [published data only]

Challiner 1994 [published data only]

Dardaine 1995 [published data only]

Delamaire 1992 [published data only]

Duems Noriega 2014 [published data only]

Hägglund 1998 [published data only]

Harbo 2009 [published data only]

Harvey 1987 [published data only]

Hubble 2001 [published data only]

Lamhaut 2010 (no PPE) [published data only]

Lamhaut 2010 (with PPE) [published data only]

Liebl 2009 [published data only]
References to studies excluded from this review

Chavez-Negrete 1991 [published data only]

Ismael 2012 [published data only]

Klementz 1997 [published data only]

Koshy 2005 [published data only]

Lee 2009 [published data only]

Mace 2013 [published data only]

Mahalanabis 1970 [published data only]

Moulin 1991 [published data only]

Nelson 1997 [published data only]

Paxton 2009 [published data only]

Rajani 2011 [published data only]

Ransome-Kuti 1969 [published data only]

Robinson 1993 [published data only]

Soremekun 2009 [published data only]

Tighe 1993 [published data only]

Additional references
Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease (Review)

Deeks 2011

Feldmann 2011

Fowler 2014

GRADEpro 2014

H限mann 2011a

Higgins 2011b

Hozo 2005

Kreuels 2014

Lefebvre 2011

Remington 2007

Ribner 2014

Rochon 1997

Rouhani 2011

Sanchez 2006

Schieffelin 2014

Schunemann 2011

TSA - Trial Sequential Analysis 0.9 Beta
Copenhagen Trial Unit, Center for Clinical Intervention Research, Rigshospitalet. TSA - Trial Sequential Analysis 0.9 Beta. Copenhagen: Copenhagen Trial Unit, Center for Clinical Intervention Research, Rigshospitalet, 2011.

Wait 2004

WHO 2014

WHO Ebola Response Team 2014

References to other published versions of this review
Ker 2014

* Indicates the major publication for the study
### Characteristics of included studies  
*ordered by study ID*

**Banerjee 1994**

<table>
<thead>
<tr>
<th>Methods</th>
<th>Parallel randomised trial</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Participants</strong></td>
<td></td>
</tr>
<tr>
<td>Setting</td>
<td>hospital emergency unit in Chandigarh, India</td>
</tr>
<tr>
<td>60 children (aged 3 months to 2 years) with severe dehydration due to diarrhoea and/or vomiting</td>
<td></td>
</tr>
<tr>
<td>Intravenous group: (n = 30); M/F = NR; mean age (SEM) = 8.6 (1.6) months</td>
<td></td>
</tr>
<tr>
<td>Intraosseous group: (n = 30); M/F = NR; mean age (SEM) = 8.9 (2.0) months</td>
<td></td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
<td></td>
</tr>
<tr>
<td>Intravenous group: 22 or 24 G Teflon catheter, insertion site not specified</td>
<td></td>
</tr>
<tr>
<td>Intraosseous group: 18 G spinal needle with stylet or 16 to 18 G hypodermic needle with stylet, insertion site not specified</td>
<td></td>
</tr>
<tr>
<td>Both groups were infused with normal saline and/or N/2 saline in 5% dextrose with potassium 20 mEq/L, if not contraindicated</td>
<td></td>
</tr>
<tr>
<td>Insertions were performed by paediatric residents with 1 year of clinical experience</td>
<td></td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td></td>
</tr>
<tr>
<td>Failure of route placement*, defined as failure to secure route within 5 minutes of first attempt</td>
<td></td>
</tr>
<tr>
<td>Time taken to secure access°</td>
<td></td>
</tr>
<tr>
<td>Serum sodium°</td>
<td></td>
</tr>
<tr>
<td>Serum potassium°</td>
<td></td>
</tr>
<tr>
<td>Urea°</td>
<td></td>
</tr>
<tr>
<td>Creatinine°</td>
<td></td>
</tr>
<tr>
<td>*data analysed as intention-to-treat</td>
<td></td>
</tr>
<tr>
<td>°data analysed as-treated</td>
<td></td>
</tr>
<tr>
<td><strong>Notes</strong></td>
<td></td>
</tr>
<tr>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>High risk</td>
<td>Participants were “assigned alternately”</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>High risk</td>
<td>Participants were “assigned alternately”</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Blinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the effect estimate would have been biased</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biased</td>
</tr>
</tbody>
</table>
Blinding of outcome assessment (detection bias)  
Clinical outcomes | Low risk | We judge that measurement of these outcomes is not likely to be influenced by lack of blinding

Blinding of outcome assessment (detection bias)  
Subjective outcomes | Unclear risk | Data on these outcomes were not reported

Incomplete outcome data (attrition bias)  
Outcomes related to parenteral route insertion | High risk | Access could not be secured in 10 patients in the IV group who were switched to the IO group. Data on success of insertion were included in the meta-analysis on an intention-to-treat basis. Time for insertion data were presented and are therefore included in the meta-analysis according to route received

Incomplete outcome data (attrition bias)  
Clinical outcomes | High risk | Data presented and therefore included in the meta-analysis according to the route received

Incomplete outcome data (attrition bias)  
Subjective outcomes | Unclear risk | Data on these outcomes were not reported

Selective reporting (reporting bias) | Unclear risk | Insufficient information to permit judgement

**Boullu-Sanchis 2006**

**Methods**  
Parallel randomised trial

**Participants**  
Setting: diabetology department, France  
37 patients hospitalised for uncontrolled type 2 diabetes  
- Intravenous group: (n = 13); M/F = 8/5; mean age (SD) = 57.9 (2.6)  
- Subcutaneous group: (n = 20); M/F = 9/11; mean age (SD) = 59.0 (1.5)

**Interventions**  
- Intravenous group: pump continuously administered solution of 0.4 ml regular insulin in 39.6 ml saline  
- Subcutaneous group: continuous infusion with intermittent bolus. Site changed every 3 days  
Unclear who performed the insertions

**Outcomes**  
Local site reactions  
’data analysed as intention-to-treat

**Notes**  
-

**Risk of bias**

**Bias** | Authors’ judgement | Support for judgement
### Boullu-Sanchis 2006  (Continued)

| Random sequence generation (selection bias) | Unclear risk | Described as "randomized by drawing to either group 1 or group 2" |
| Allocation concealment (selection bias) | Unclear risk | Not described |
| Blinding of participants and personnel (performance bias) | High risk | Blinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biased |
| Blinding of outcome assessment (detection bias) Outcomes related to parenteral route insertion | Unclear risk | Data on these outcomes were not reported |
| Blinding of outcome assessment (detection bias) Clinical outcomes | Unclear risk | Not applicable (trial does not involve fluid administration) |
| Blinding of outcome assessment (detection bias) Subjective outcomes | High risk | Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biased |
| Incomplete outcome data (attrition bias) Outcomes related to parenteral route insertion | Unclear risk | Data on these outcomes were not reported |
| Incomplete outcome data (attrition bias) Clinical outcomes | Unclear risk | Data on these outcomes were not reported |
| Incomplete outcome data (attrition bias) Subjective outcomes | Low risk | 4 patients (2 in each group) were excluded, however we judged that the reasons for the missing data are unlikely to be related to outcome |
| Selective reporting (reporting bias) | Unclear risk | Insufficient information to permit judgement |

### Challiner 1994

| Methods | Parallel randomised trial |
| Participants | Setting: elderly care unit, UK  34 elderly stroke patients requiring parenteral nutrition because of impaired consciousness or dysphagia  
  - Intravenous group: (n = 17); M/F = 6/11; mean age (range) = 84.2 (71 to 95) years  
  - Subcutaneous group: (n = 17); M/F = 6/11; mean age (range) = 82.8 (69 to 93) years |
| Interventions | - Intravenous group: details of route not described  
  - Subcutaneous group: 10 G butterfly cannula sited on the trunk, axillary, scapular |
or thigh area. 1500 units of hyaluronidase added to each bag if infusion ran behind time
Both groups infused with 2 litres of isotonic dextrose-saline per 24 hours over 3 days
Unclear who performed the insertions

| Outcomes | Local site reactions
| Mortality
| "data analysed as intention-to-treat"

| Notes | - |

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Computer-generated</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Sequentially numbered, sealed envelopes</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Blinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Outcomes related to parenteral route insertion</td>
<td>High risk</td>
<td>Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Clinical outcomes</td>
<td>Low risk</td>
<td>We judge that measurement of these outcomes is not likely to be influenced by lack of blinding</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Subjective outcomes</td>
<td>High risk</td>
<td>Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Outcomes related to parenteral route insertion</td>
<td>High risk</td>
<td>2 patients allocated to the subcutaneous group were excluded from the trial analysis - 1 died and 1 developed local oedema</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Clinical outcomes</td>
<td>Low risk</td>
<td>Data for the patient in the subcutaneous group excluded from the trial analysis have been included in the meta-analysis for the mortality outcome</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Subjective outcomes</td>
<td>Low risk</td>
<td>Data for the patient in the subcutaneous group excluded from the trial analysis have been included in the meta-analysis for the local site reactions (oedema) outcome</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Insufficient information to permit judgement</td>
</tr>
</tbody>
</table>
### Methods
Randomised cross-over trial

### Participants
Setting: hospital, France
6 hospitalised, elderly patients who had been admitted at least 45 days before, for rehabilitation after a bone trauma requiring surgery
M/F = 1/5; mean age (SD) = 81.5 (9.8) years

### Interventions
- Intravenous group: administered into forearm vein
- Subcutaneous group: administered into the anterior wall of the abdomen
Both groups infused with 1000 ml of 5% glucose solution containing 4 g NaCl over 6 hours
Unclear who performed the insertions

### Outcomes
None of interest to this review

### Notes
-

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not described</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not described</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Blinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Data on this outcome were not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Data on this outcome were not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>No exclusions described</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>Data on this outcome were not reported</td>
</tr>
</tbody>
</table>
### Delamaire 1992

<table>
<thead>
<tr>
<th><strong>Methods</strong></th>
<th>Parallel randomised trial</th>
</tr>
</thead>
</table>
| **Participants** | Setting: hospital, France  
30 elderly patients (average 83 years) requiring rehydration (unable to take sufficient oral hydration)  
- Intravenous group: (n = 15); M/F = 6/11; mean age (SD) = NR  
- Subcutaneous group: (n = 15); M/F = NR; mean age (SD) = NR |
| **Interventions** | - Intravenous group:  
- Subcutaneous group:  
Both groups infused with 1 litre solution of 2.5% glucose + 4.5g sodium chloride  
Unclear who performed the insertions |
| **Outcomes** | Failures of route replacement, definition of failure not described  
Local site reactions (oedema, infection)  
*data analysed as intention-to-treat* |
| **Notes** | - |

### Risk of bias

<table>
<thead>
<tr>
<th><strong>Bias</strong></th>
<th><strong>Authors’ judgement</strong></th>
<th><strong>Support for judgement</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not described</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not described</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Blinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Outcomes related to parenteral route insertion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
<tr>
<td>Clinical outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risk of bias</td>
<td>Delamaire 1992 (Continued)</td>
<td>Duems Noriega 2014</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Subjective outcomes</td>
<td>High risk</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Clinical outcomes</td>
<td>Unclear risk</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Subjective outcomes</td>
<td>Low risk</td>
</tr>
<tr>
<td>Duems Noriega 2014</td>
<td>Methods</td>
<td>Parallel randomised trial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Duems Noriega 2014

**Bias** | **Authors’ judgement** | **Support for judgement**
---|---|---
Random sequence generation (selection bias) | Unclear risk | Not described
Allocation concealment (selection bias) | Unclear risk | Randomisation by mixed blocks of 6 sealed envelopes. Each block with 3 cards with the treatment IV and 3 with SC
Blinding of participants and personnel (performance bias) All outcomes | High risk | Blinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biased
Blinding of outcome assessment (detection bias) Outcomes related to parenteral route insertion | High risk | Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biased
Blinding of outcome assessment (detection bias) Clinical outcomes | Low risk | We judge that measurement of these outcomes is not likely to be influenced by lack of blinding
Blinding of outcome assessment (detection bias) Subjective outcomes | High risk | Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biased
Incomplete outcome data (attrition bias) Outcomes related to parenteral route insertion | High risk | 3 patients who died during the study period were excluded from the trial analysis
Incomplete outcome data (attrition bias) Clinical outcomes | High risk | Data for the 3 patients (2 in the intravenous group, 1 in the subcutaneous group) who died during the study period were excluded from the trial analysis. These data have been included in the meta-analysis for the mortality outcome. However, risk of bias remains for renal function outcomes
Incomplete outcome data (attrition bias) Subjective outcomes | High risk | 3 patients who died during the study period were excluded from the trial analysis
Selective reporting (reporting bias) | Unclear risk | Insufficient information to permit judgement

### Harbo 2009

**Methods** | Randomised cross-over trial

**Participants** | Setting: Aarhus University Hospital, Denmark
10 intravenous immunoglobulin responsive patients with multifocal motor neuropathy
M/F = 4/5; mean age (SD) = 49.2 (10.51) years
### Interventions
- **Intravenous group:** administered during hospital admission through a permanent IV catheter inserted into the subclavian vein (n = 2) or peripheral vein (n = 7)
- **Subcutaneous group:** syringe pump and butterfly needle into tissue at the abdominal wall. Received 80 to 155 ml at 4 to 8 injection sites each week at an infusion time of 2 to 4 hours

Both groups infused with immunoglobulin

Unclear who performed the IV insertions; SC insertions performed initially by nurse and then were self administered

### Outcomes
- Local site reactions (erythema, oedema, infection)
- Pain *(how this was assessed is not described in the report)*

‘data analysed as intention-to-treat’

‘data included in review as a parallel trial; this approach leads to a unit of analysis error, causing the CIs to be too wide and the trial to receive too little weight’

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not described</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Pharmacy-controlled</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Blinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Outcomes related to parenteral route insertion</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Clinical outcomes</td>
<td>Unclear risk</td>
<td>Not applicable (trial does not involve fluid administration)</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Subjective outcomes</td>
<td>High risk</td>
<td>Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Outcomes related to parenteral route insertion</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Clinical outcomes</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
<tr>
<td>Risk of bias</td>
<td>Authors’ judgement</td>
<td>Support for judgement</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------</td>
<td>-------------------</td>
<td>-------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not described</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not described</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Blinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Not applicable (trial does not involve fluid administration)</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biased</td>
</tr>
</tbody>
</table>

**Harvey 1987**

**Methods**
Randomised cross-over trial

**Participants**
Setting: London, UK
9 patients with malignant disease
M/F = NR; mean age (SD) = NR

**Interventions**
- Intravenous group: into forearm vein via Teflon catheter
- Subcutaneous group: into anterior abdominal wall via 25 G steel needle
15 mg bleomycin in saline with 100 mg hydrocortisone
Unclear who performed the insertions

**Outcomes**
Local site reactions, although insufficient data presented for meta-analysis

**Notes**
-
### Harvey 1987  (Continued)

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete outcome data (attrition bias) Outcomes related to parenteral route insertion</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Clinical outcomes</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Subjective outcomes</td>
<td>Unclear risk</td>
<td>No exclusions reported, although presented data were insufficient for meta-analysis</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Insufficient information to permit judgement</td>
</tr>
</tbody>
</table>

### Hubble 2001

<table>
<thead>
<tr>
<th>Methods</th>
<th>Randomised cross-over trial</th>
</tr>
</thead>
</table>
| Participants           | Setting: hospital training laboratory, USA  
13 students of the senior class of baccalaureate degree paramedical programme, recently trained in both methods  
M/F = NR; mean age (SD) = NR |
| Interventions          | Saphenous vein cutdown: at the ankle in a cadaver using standard technique with insertion of an IV cannula under direct visualisation  
Intraosseous group: using the BIG® into the proximal tibia of a cadaver  
Both access routes connected to a 1000 ml bag of NaCl solution  
Insertions performed by members of senior class of a baccalaureate degree paramedical programme |
| Outcomes               | Failure of route placement *(defined as inability to initiate fluid flow)  
Time to infusion †  
*Data analysed as intention-to-treat  
†Data included in review as a parallel trial; this approach leads to a unit of analysis error, causing the CIs to be too wide and the trial to receive too little weight |
| Notes                  | -                           |

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not described</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not described</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Blinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biased</td>
</tr>
</tbody>
</table>
### Hubble 2001 (Continued)

<table>
<thead>
<tr>
<th>Bias Type</th>
<th>Risk</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Outcomes related to parenteral route insertion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Not applicable (simulated using a cadaver)</td>
</tr>
<tr>
<td>Clinical outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
<tr>
<td>Subjective outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>No exclusions</td>
</tr>
<tr>
<td>Outcomes related to parenteral route insertion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>Not applicable (simulated using a cadaver)</td>
</tr>
<tr>
<td>Clinical outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>No exclusions</td>
</tr>
<tr>
<td>Subjective outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Insufficient information to permit judgement</td>
</tr>
</tbody>
</table>

### Hägglund 1998

<table>
<thead>
<tr>
<th>Method</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Parallel randomised trial</td>
</tr>
</tbody>
</table>
| Participants | Setting: Huddinge Hospital, Sweden 38 adult patients receiving bone marrow transplants from related donor  
- Intravenous group: (n = 20); M/F = NR; median age (range) = 38 (19 to 54) years  
- Intraosseous group: (n = 9); M/F = NR; median age (range) = 38 (20 to 50) years |
| Interventions |  
- Intravenous group: details of route not described  
- Intraosseous group: 2 bone marrow aspiration needles inserted into each side of the posterior iliac crests under local anaesthesia. Infusion given with or without overpressure using a 50 cc syringe  
Both groups infused with bone marrow  
Unclear who performed the insertions |
| Outcomes | Local site reactions (infection)*  
\* data not analysed on an intention-to-treat basis; data on patient who switched treatment excluded from trial analysis |
| Notes | - |

**Risk of bias**

---

Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease (Review)  
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Hägglund 1998 (Continued)

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not described</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not described</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Blinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
<tr>
<td>Outcomes related to parenteral route insertion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Not applicable (trial does not involve fluid administration)</td>
</tr>
<tr>
<td>Clinical outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Subjective outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
<tr>
<td>Outcomes related to parenteral route insertion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>Not applicable (trial does not involve fluid administration)</td>
</tr>
<tr>
<td>Clinical outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>High risk</td>
<td>Apparent from the report that 1 patient in the IO group switched to receive half the volume as an IV infusion because of severe pain and was excluded from the analysis</td>
</tr>
<tr>
<td>Subjective outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Insufficient information to permit judgement</td>
</tr>
</tbody>
</table>

### Lamhaut 2010 (no PPE)

<table>
<thead>
<tr>
<th>Methods</th>
<th>Randomised cross-over trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>Setting: pre-hospital department of a hospital, France 25 pre-hospital emergency professionals (9 nurses and 16 physicians) M/F = NR; mean age (SD) = NR</td>
</tr>
<tr>
<td>Interventions</td>
<td>• Intravenous group: single-use 18 G peripheral intravenous catheter inserted into a training manikin  • Intravenous group + CBRN: as above while wearing CBRN protective equipment</td>
</tr>
</tbody>
</table>
Lamhaut 2010 (no PPE)  (Continued)

| Outcomes | Insertion failures, not clearly defined, described only as “failure of an IV or IO access attempt, including the case of absence of fluid after connection of the infusion line to the vascular access”
| Time to infusion |
| 'data analysed as intention-to-treat' |

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Computer-generated randomisation</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not described</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Blinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Outcomes related to parenteral route insertion</td>
<td>High risk</td>
<td>Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Clinical outcomes</td>
<td>Unclear risk</td>
<td>Not applicable (simulated using manikin)</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Subjective outcomes</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Outcomes related to parenteral route insertion</td>
<td>Low risk</td>
<td>No exclusions</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Clinical outcomes</td>
<td>Unclear risk</td>
<td>Not applicable (simulated using a manikin)</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Subjective outcomes</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
</tbody>
</table>
**Selective reporting (reporting bias)** | Unclear risk | Insufficient information to permit judgement  
---|---|---

### Lamhaut 2010 (with PPE)

#### Methods

Randomised cross-over trial

#### Participants

Setting: pre-hospital department of a hospital, France  
25 pre-hospital emergency professionals (9 nurses and 16 physicians)  
M/F = NR; mean age (SD) = NR

#### Interventions

- Intravenous group + CBRN: as above while wearing CBRN protective equipment  
- Intraosseous group + CBRN: as above while wearing CBRN protective equipment  
Both access routes connected to bag of fluid solution

#### Outcomes

Insertion failures*, not clearly defined, described only as “failure of an IV or IO access attempt, including the case of absence of fluid after connection of the infusion line to the vascular access”  
Time to infusion*  
*data analysed as intention-to-treat

#### Notes

- 

---

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Computer-generated randomisation</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not described</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Blinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Outcomes related to parenteral route insertion</td>
<td>High risk</td>
<td>Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Clinical outcomes</td>
<td>Unclear risk</td>
<td>Not applicable (trial does not involve fluid administration)</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Subjective outcomes</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
</tbody>
</table>
### Lamhaut 2010 (with PPE)  
(Continued)

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete outcome data (attrition bias) Outcomes related to parenteral route insertion</td>
<td>Low risk</td>
<td>No exclusions</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Clinical outcomes</td>
<td>Unclear risk</td>
<td>Not applicable (trial does not involve fluid administration)</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Subjective outcomes</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Insufficient information to permit judgement</td>
</tr>
</tbody>
</table>

### Liebl 2009

<table>
<thead>
<tr>
<th>Methods</th>
<th>Randomised cross-over trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>Setting: centres in Netherlands, France, Austria, Germany and Switzerland 61* patients with type 1 diabetes with frequent hypoglycaemia and/or HbA1c &gt; 7.0% M/F = 44/16; mean age (SD) = 50.5 (10.8) years (*1 patient excluded)</td>
</tr>
</tbody>
</table>
| Interventions                                                          | • Intraperitoneal: using the DiaPort system, implanted under general anaesthesia into the subcutaneous tissue of the abdominal wall. Insulin is infused into the abdominal cavity  
  • Subcutaneous group: continuous infusion of insulin lispro  
  Unclear who performed the insertions |
| Outcomes                                                               | Local site reactions (infections and inflammations)*  
  Pain* (how this was assessed is not described in the report) |
| Notes                                                                  | *data analysed as-treated |

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not described</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not described</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Blinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biased</td>
</tr>
</tbody>
</table>
### Liebl 2009 (Continued)

<table>
<thead>
<tr>
<th>Blinding of outcome assessment (detection bias)</th>
<th>Unclear risk</th>
<th>Data on these outcomes were not reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcomes related to parenteral route insertion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Not applicable (trial does not involve fluid administration)</td>
</tr>
<tr>
<td>Clinical outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Subjective outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
<tr>
<td>Outcomes related to parenteral route insertion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>Not applicable (trial does not involve fluid administration)</td>
</tr>
<tr>
<td>Clinical outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>High risk</td>
<td>Large number of dropouts during study - 15 IP patients and 9 SC patients dropped out during first treatment period followed by 9 IP patients and 3 SC patients during the second treatment period</td>
</tr>
<tr>
<td>Subjective outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Insufficient information to permit judgement</td>
</tr>
</tbody>
</table>

### O’Keeffe 1996

**Methods**
Parallel randomised trial

**Participants**
Setting: acute geriatric unit, UK
60 elderly patients with cognitive impairment judged to require parenteral fluids for at least 48 hours because of mild dehydration or poor oral intake
- Intravenous group: (n = 30); M/F = 13/17; mean age (SD) = 84 (7) years
- Subcutaneous group: (n = 30); M/F = 10/20; mean age (SD) = 81 (6) years

**Interventions**
- Intravenous group: administered through an 18 or 20 G cannula in forearm vein
- Subcutaneous group: administered in the infraclavicular, scapular, abdominal or thigh areas through a 21 G butterfly cannula
Up to 2 litres of any combination of 0.9% normal saline, 0.45% normal saline and 5% dextrose
Unclear who performed the insertions

**Outcomes**
- Local site reactions (oedema)
- Patient discomfort (agitation related to cannula or drip)
- Volume of fluids infused
- data not analysed on an intention-to-treat basis; data on patient who switched treatment
**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Random numbers table</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Sealed envelopes</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Blinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Outcomes related to parenteral route insertion</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Clinical outcomes</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Subjective outcomes</td>
<td>High risk</td>
<td>Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Outcomes related to parenteral route insertion</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Clinical outcomes</td>
<td>High risk</td>
<td>2 patients were excluded from the trial analyses (1 IV patient was switched to SC fluids and 1 patient in the SC group died). However, the mortality data were included in the meta-analysis</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Subjective outcomes</td>
<td>High risk</td>
<td>2 patients were excluded from the trial analyses (1 IV patient was switched to SC fluids and 1 patient in the SC group died)</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Insufficient information to permit judgement</td>
</tr>
</tbody>
</table>
Reades 2011

Methods
- Parallel randomised trial

Participants
- Setting: pre-hospital setting in North Carolina, USA
  - 182 adult patients with non-traumatic out-of-hospital cardiac arrest
    - Intravenous group: (n = 67); M/F = 42/25; mean age (SD) = 64.7 (2.2) years
    - Intraosseous group 1: (n = 51); M/F = 36/15; mean age (SD) = 61.2 (2.4) years
    - Intraosseous group 2: (n = 64); M/F = 41/23; mean age (SD) = 66.9 (2.1) years

Interventions
- Intravenous group: inserted into any accessible peripheral vein but preferably at the antecubital fossa
- Intraosseous group 1: inserted into proximal humerus defined as the greater tubercle of the anterior humeral head 1 cm proximal to the surgical neck of humerus using EZ-IO®
- Intraosseous group 2: inserted into the proximal tibia located medial to the tibial tuberosity, or just below the patella along the flat aspect of the tibia using EZ-IO®
  - Data for intraosseous groups 1 and 2 were combined for the purpose of meta-analysis
  - Insertions performed by paramedics

Outcomes
- Failure of route placement* ('first-attempt' success was defined for IO insertion as secure placement of the catheter within the bone cavity and for IV insertion as secure placement within a peripheral vein. If initial access was not successful, the paramedics used their own judgement for choosing the subsequent site)
- Time taken to secure access‡
- Average number of insertion attempts*‡*‡
- Dislodgements of access method*
- Paramedics' reported comfort with insertion method**
- Volume of fluid infused‡
  - *not specified in trial registration record
  - ‡mean and SD estimated from reported median and IQR for analysis - moderate sample size therefore SD calculated as = range/4
  - *data analysed as intention-to-treat

Notes
- Prior to the study, all paramedics were trained on IO insertions using EZ-IO® on a human cadaver

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not described</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>High risk</td>
<td>300 note cards were prepared in advance and labelled with a vascular access method. Each note card was sealed in a blank, numbered envelope. Each crew randomly selected and opened an envelope prior to every shift. The route selected was applied to the crew's first cardiac arrest of the day</td>
</tr>
</tbody>
</table>
### Reades 2011

(Continued)

<table>
<thead>
<tr>
<th>Bias Type</th>
<th>Risk Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Blinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Outcomes related to parenteral route insertion</td>
<td>High risk</td>
<td>Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Clinical outcomes</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Subjective outcomes</td>
<td>High risk</td>
<td>Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Outcomes related to parenteral route insertion</td>
<td>Low risk</td>
<td>The allocated method was not used in 13 patients due to “human error or situations beyond the control of the paramedic” (9 in the humeral IO group and 4 in the IV group). Success of insertion data was analysed on both an intention-to-treat and as-treated basis. Other outcomes were analysed as intention-to-treat</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Clinical outcomes</td>
<td>Low risk</td>
<td>Analysed as intention-to-treat</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Subjective outcomes</td>
<td>Low risk</td>
<td>Analysed as intention-to-treat</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>High risk</td>
<td>Prospectively registered (NCT01119807). Additional secondary outcomes were reported in the final report that were not mentioned in the registration record</td>
</tr>
</tbody>
</table>

### Selam 1983

<table>
<thead>
<tr>
<th>Methods</th>
<th>Randomised cross-over trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>Setting: hospital, France 6 patients with insulin-dependent diabetes M/F = 2/7; mean age (SE) = 35 (4) years</td>
</tr>
<tr>
<td>Interventions</td>
<td>• Intravenous group: implanted either surgically in the cephalic vein or directly in the subclavian vein by using a needle puncture technique  • Subcutaneous group: catheter implanted in the subcutaneous tissue of the lateral abdomen  • Intraperitoneal group: inserted surgically into the lateral abdomen under local anaesthesia through a 5 cm subumbilical laparotomy</td>
</tr>
</tbody>
</table>
All groups were infused insulin
Unclear who performed the insertions

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Local site reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pain (how this was assessed is not described in the report)</td>
</tr>
<tr>
<td></td>
<td>'data analysed as intention-to-treat'</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Notes</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Risk of bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bias</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not described</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not described</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Blinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Outcomes related to parenteral route insertion</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Clinical outcomes</td>
<td>Unclear risk</td>
<td>Not applicable (trial does not involve fluid administration)</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Subjective outcomes</td>
<td>High risk</td>
<td>Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the effect estimate may have been biased</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Outcomes related to parenteral route insertion</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Clinical outcomes</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Subjective outcomes</td>
<td>Low risk</td>
<td>No exclusions</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Insufficient information to permit judgement</td>
</tr>
</tbody>
</table>
### Slesak 2003

<table>
<thead>
<tr>
<th>Methods</th>
<th>Parallel randomised trial</th>
</tr>
</thead>
</table>

| Participants | Setting: hospital geriatric department, Germany  
96 hospitalised patients aged 60 years and over with mild to moderate dehydration  
- Intravenous group: (n = 48); M/F = 12/36; mean age (SD) = 85.3 (5.8) years  
- Subcutaneous group: (n = 14); M/F = 17/31; mean age (SD) = 85.3 (7.6) years |

| Interventions | - Intravenous group: 18 to 22 G peripheral catheters  
- Subcutaneous group: 21 G butterfly into thigh, abdomen or thorax  
Both groups infused with half-normal saline-glucose solutions for as long as clinically necessary  
Insertions performed by nurses and doctors |

| Outcomes | Time to infusion  
Time with functional access  
Local site reactions (oedema, erythema, cellulitis, phlebitis, pain)  
Doctors and nurses feasibility of route scores ('feasibility' described in the trial report as "with regard to the practical implementation and the occurrence of complications")  
Patient discomfort (measured using a Likert-like scale, points ranging from 1 = very good to 6 = very bad)  
Volume of fluid infused  
Serum sodium  
Creatinine  
‡mean and SD estimated from reported median and IQR for analysis - moderate sample size therefore SD calculated as range/4  
*mean and SD estimated from reported median and minimum-maximum values for analysis - moderate sample size therefore SD calculated as range/4  
*data analysed as intention-to-treat |

| Notes | - |

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not described</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Shuffled blocks of 6 sealed envelopes, each containing 3 of each treatment</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Blinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Outcomes related to parenteral route insertion</td>
<td>High risk</td>
<td>Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biased</td>
</tr>
</tbody>
</table>
**Slesak 2003**  
(Continued)

| Blinding of outcome assessment (detection bias) | Clinical outcomes | Low risk | We judge that measurement of these outcomes is not likely to be influenced by lack of blinding |
| Blinding of outcome assessment (detection bias) | Subjective outcomes | High risk | Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biased |
| Incomplete outcome data (attrition bias) | Outcomes related to parenteral route insertion | Low risk | No exclusions reported. However, 13 patients in the SC group were switched to IV and 17 patients in the IV group were switched to SC. Data were analysed according to intention-to-treat |
| Incomplete outcome data (attrition bias) | Clinical outcomes | Low risk | No exclusions reported. However, 13 patients in the SC group were switched to IV and 17 patients in the IV group were switched to SC. Data were analysed according to intention-to-treat |
| Incomplete outcome data (attrition bias) | Subjective outcomes | Low risk | No exclusions reported. However, 13 patients in the SC group were switched to IV and 17 patients in the IV group were switched to SC. Data were analysed according to intention-to-treat |
| Selective reporting (reporting bias) | Unclear risk | Insufficient information to permit judgement |

**Spandorfer 2005**

| Methods | Parallel randomised trial |
| Setting: 24 hospitals, USA |
| 148 children with mild to moderate dehydration aged 1 month to < 10 years |
|  • Intravenous group: (n = 75); M/F = 39/36; mean age (range) = 2.4 (2.07) years |
|  • Subcutaneous group: (n = 73); M/F = 34/39; mean age (range) = 2.1 (1.72) years |

| Interventions |
|  • Intravenous group: details of route not described |
|  • Subcutaneous group: details of route not described. Hyaluronidase used in all patients |
|  20 ml/kg isotonic fluids over 1 hour |
|  Insertions performed by “health care providers” |

| Outcomes |
| Failure of route placement † (definition of failure not specified in the report) |
| Time to infusion † |
| Local site reactions (erythema, oedema, swelling) † |
| Clinicians’ perception of ease of route to perform † |
| Patient discomfort † (assessed using the FLACC scale for those < 3 years or FACES Pain Rating scale for those ≥ 3 years) |
| Volume of fluid infused † |
| †data analysed as intention-to-treat |

*Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease (Review)*

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Computer-generated randomisation</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Central randomisation</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Blinding not feasible. Likely that lack of blinding introduced bias, but unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Outcomes related to parenteral route insertion</td>
<td>High risk</td>
<td>Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Clinical outcomes</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) Subjective outcomes</td>
<td>High risk</td>
<td>Likely that lack of blinding biased the assessment of these outcomes; unclear in which direction the results would have been biased</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Outcomes related to parenteral route insertion</td>
<td>Low risk</td>
<td>1 patient in the IV group was excluded from the trial at the request of the parent. 15 patients in the IV group were switched to SC. Both intention-to-treat and as-treated data are presented</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Clinical outcomes</td>
<td>Unclear risk</td>
<td>Data on these outcomes were not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) Subjective outcomes</td>
<td>Low risk</td>
<td>1 patient in the IV group was excluded from the trial at the request of the parent. 15 patients in the IV group were switched to SC. Both intention-to-treat and as-treated data are presented</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Insufficient information to permit judgement</td>
</tr>
</tbody>
</table>

CBRN: chemical, biological, radiological and nuclear (protective equipment)
CI: confidence interval
F: female
FLACC scale: Face, Legs, Activity, Cry, Consolability scale
IO: intraosseous
Characteristics of excluded studies [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chavez-Negrete 1991</td>
<td>Trial in which patients were randomised to receive an infusion of 7.5% NaCl + 6% dextran 60 or Ringer's lactate. Within each arm some of the patients received the assigned fluids intravenously and others intraosseously. However, the parenteral method for infusion was not determined at random, so the trial was not eligible for inclusion in this review</td>
</tr>
<tr>
<td>Ismael 2012</td>
<td>The parenteral methods under study were not used for infusion of fluids or medication</td>
</tr>
<tr>
<td>Klemenz 1997</td>
<td>Not a RCT; the article is a letter describing the subcutaneous and intravenous methods for delivering fluids</td>
</tr>
<tr>
<td>Koshy 2005</td>
<td>Not relevant to the review question; the purpose of the trial was to assess the effects of the infusion of analgesia on cancer pain</td>
</tr>
<tr>
<td>Lee 2009</td>
<td>The parenteral methods under study were not used for infusion of fluids or medication</td>
</tr>
<tr>
<td>Mace 2013</td>
<td>Not a RCT. The study evaluated the cost-effectiveness of subcutaneous fluid administration compared to intravenous fluid administration in children with mild to moderate dehydration</td>
</tr>
<tr>
<td>Mahalanabis 1970</td>
<td>Not a RCT. The study explores the effect of intraperitoneal routes in dehydrated patients. All patients received fluids via both the intravenous and intraperitoneal routes</td>
</tr>
<tr>
<td>Moulin 1991</td>
<td>Not relevant to the review question; the purpose of the trial was to assess the effects of the infusion of analgesia on cancer pain</td>
</tr>
<tr>
<td>Nelson 1997</td>
<td>Cross-over study comparing intravenous and subcutaneous morphine. However, the order in which the patients received the methods was not randomised - all received intravenous morphine followed by subcutaneous morphine</td>
</tr>
<tr>
<td>Paxton 2009</td>
<td>Not a RCT. This is a prospective cohort study exploring intraosseous and intravenous access</td>
</tr>
<tr>
<td>Rajani 2011</td>
<td>Comparison of umbilical venous access versus intraosseous access under simulated conditions. Umbilical venous access was not an eligible type of intervention</td>
</tr>
<tr>
<td>Reference</td>
<td>Description</td>
</tr>
<tr>
<td>-------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Ransome-Kuti 1969</td>
<td>Not a RCT. This is a case series report describing the outcomes of 91 dehydrated babies who were administered fluids via the intraperitoneal route</td>
</tr>
<tr>
<td>Robinson 1993</td>
<td>The parenteral methods under study were not used for infusion of fluids or medication</td>
</tr>
<tr>
<td>Soremekun 2009</td>
<td>Cross-over study comparing intravenous and subcutaneous glucose. However, the order in which the patients received the methods was not randomised - all received intravenous access first followed by subcutaneous access</td>
</tr>
<tr>
<td>Tighe 1993</td>
<td>Not a RCT. This is a case series report describing the outcomes of 9 dehydrated children who were administered fluids via the intravenous, intraosseous or intraperitoneal route. The route received was not allocated at random</td>
</tr>
</tbody>
</table>

NaCl: sodium chloride
RCT: randomised controlled trial
## DATA AND ANALYSES

### Comparison 1. Intravenous versus intraosseous access

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Insertion failures</td>
<td>2</td>
<td>242</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>3.89 [2.39, 6.33]</td>
</tr>
<tr>
<td>2 Insertion failures (subgroup analysis child vs adult)</td>
<td>2</td>
<td>242</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>3.89 [2.39, 6.33]</td>
</tr>
<tr>
<td>2.1 Adult</td>
<td>1</td>
<td>182</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>3.24 [2.00, 5.27]</td>
</tr>
<tr>
<td>2.2 Child</td>
<td>1</td>
<td>60</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>21.0 [1.29, 342.93]</td>
</tr>
<tr>
<td>3 Time to infusion/placement</td>
<td>4</td>
<td></td>
<td>Mean Difference (Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>4 Average number of insertion attempts</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>5 Dislodgement of device during infusion</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>6 Local site reactions</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>6.1 Infection</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>7 Clinician's perception of ease/feasibility of administration</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>8 Volume of fluids transfused</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>9 Electrolyte level</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>9.1 Sodium</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>9.2 Potassium</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>10 Renal function</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>10.1 Urea</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
<tr>
<td>10.2 Creatinine</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>0.0 [0.0, 0.0]</td>
</tr>
</tbody>
</table>

### Comparison 2. Intravenous versus subcutaneous access

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Insertion failures</td>
<td>3</td>
<td>238</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>14.79 [2.87, 76.08]</td>
</tr>
<tr>
<td>2 Insertion failures (sensitivity analysis - trial(s) with adequate allocation concealment)</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>3 Insertion failures (subgroup analysis child vs adult)</td>
<td>3</td>
<td>238</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>14.79 [2.87, 76.08]</td>
</tr>
<tr>
<td>3.1 Adult</td>
<td>2</td>
<td>90</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>6.0 [0.76, 47.39]</td>
</tr>
<tr>
<td>3.2 Child</td>
<td>1</td>
<td>148</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>32.13 [1.96, 525.87]</td>
</tr>
<tr>
<td>4 Time to infusion/placement</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>5 Dislodgement of device during infusion</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>6 Time with functional access (days)</td>
<td>1 Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>--------------------------------------</td>
<td>---------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 Local site reactions</td>
<td></td>
<td>Subtotals only</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.1 Any</td>
<td>9</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.2 Erythema</td>
<td>5</td>
<td>247</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.3 Swelling</td>
<td>4</td>
<td>296</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.4 Infection</td>
<td>1</td>
<td>148</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.5 Phlebitis</td>
<td>3</td>
<td>181</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.6 Oedema</td>
<td>7</td>
<td>453</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 Local site reactions (sensitivity analysis - trial(s) with adequate allocation concealment)</td>
<td>3 Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Subtotals only</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.1 Any</td>
<td>3</td>
<td>202</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.2 Erythema</td>
<td>3</td>
<td>200</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.3 Swelling</td>
<td>1</td>
<td>148</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.4 Infection</td>
<td>1</td>
<td>18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.5 Phlebitis</td>
<td>1</td>
<td>18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.6 Oedema</td>
<td>3</td>
<td>202</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 Clinicians’ scores of feasibility of insertion</td>
<td>1 Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.1 Doctors’ scores</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.2 Nurses’ scores</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 Clinician’s perception of difficulty of insertion</td>
<td>1 Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 Patients’ discomfort</td>
<td>5</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.1 Pain</td>
<td>3</td>
<td>262</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.2 Agitation</td>
<td>2</td>
<td>125</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 Patients’ discomfort (sensitivity analysis - trial(s) with adequate allocation concealment)</td>
<td>2 Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Subtotals only</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.1 Pain</td>
<td>2</td>
<td>166</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13 Patient discomfort score</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14 Mortality</td>
<td>2</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15 Mortality (sensitivity analysis - trial(s) with adequate allocation concealment)</td>
<td>1 Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16 Volume of fluids transfused</td>
<td>4</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17 Volume of fluids transfused (sensitivity analysis - trial(s) with adequate allocation)</td>
<td>1 Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18 Electrolyte level</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.1 Sodium</td>
<td>1</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19 Markers of renal function</td>
<td>2</td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.1 Urea</td>
<td>1</td>
<td>67</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.2 Creatinine</td>
<td>2</td>
<td>138</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease (Review)  
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Comparison 3. Saphenous vein cutdown versus intraosseous access

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Insertion failures</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2 Time to infusion/placement (seconds)</td>
<td>1</td>
<td></td>
<td>Mean Difference (Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
</tbody>
</table>

#### Analysis 1.1. Comparison 1 Intravenous versus intraosseous access, Outcome 1 Insertion failures.

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: 1 Intravenous versus intraosseous access

Outcome: 1 Insertion failures

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Intraosseous</th>
<th>Risk Ratio M-H,Fixed,95% CI</th>
<th>Weight</th>
<th>Risk Ratio M-H,Fixed,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Banerjee 1994</td>
<td>10/30</td>
<td>0/30</td>
<td>3.6 %</td>
<td>21.00  [1.29, 342.93]</td>
<td></td>
</tr>
<tr>
<td>Reades 2011</td>
<td>34/67</td>
<td>18/115</td>
<td>96.4 %</td>
<td>3.24   [2.00, 5.27]</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>97</strong></td>
<td><strong>145</strong></td>
<td></td>
<td><strong>100.0 %</strong></td>
<td><strong>3.89 [2.39, 6.33]</strong></td>
</tr>
</tbody>
</table>

Total events: 44 (Intravenous), 18 (Intraosseous)
Heterogeneity: Chi² = 1.94, df = 1 (P = 0.16); I² =48%
Test for overall effect: Z = 5.45 (P < 0.00001)
Test for subgroup differences: Not applicable
### Analysis 1.2. Comparison 1 Intravenous versus intraosseous access, Outcome 2 Insertion failures (subgroup analysis child vs adult).

**Review:** Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

**Comparison:** 1 Intravenous versus intraosseous access

**Outcome:** 2 Insertion failures (subgroup analysis child vs adult)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Intraosseous</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Fixed,95% CI</td>
<td></td>
<td>M-H,Fixed,95% CI</td>
</tr>
<tr>
<td><strong>1 Adult</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reades 2011</td>
<td>34/67</td>
<td>18/115</td>
<td>96.4 %</td>
<td>3.24 [ 2.00, 5.27 ]</td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>67</strong></td>
<td><strong>115</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total events:</td>
<td>34 (Intravenous), 18 (Intraosseous)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity:</td>
<td>not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect:</td>
<td>Z = 4.75 (P &lt; 0.00001)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>2 Child</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Banerjee 1994</td>
<td>10/30</td>
<td>0/30</td>
<td>3.6 %</td>
<td>21.00 [ 1.29, 342.93 ]</td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>30</strong></td>
<td><strong>30</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total events:</td>
<td>10 (Intravenous), 0 (Intraosseous)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity:</td>
<td>not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect:</td>
<td>Z = 2.14 (P = 0.033)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>97</strong></td>
<td><strong>145</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total events:</td>
<td>44 (Intravenous), 18 (Intraosseous)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity:</td>
<td>Chi$^2 = 1.94, df = 1 (P = 0.16); I^2 = 48%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect:</td>
<td>Z = 5.45 (P &lt; 0.00001)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for subgroup differences:</td>
<td>Chi$^2 = 1.67, df = 1 (P = 0.20); I^2 = 40%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Total events:** 44 (Intravenous), 18 (Intraosseous)

**Heterogeneity:** Chi$^2 = 1.94, df = 1 (P = 0.16); I^2 = 48%

**Test for overall effect:** Z = 5.45 (P < 0.00001)

**Test for subgroup differences:** Chi$^2 = 1.67, df = 1 (P = 0.20); I^2 = 40%
Analysis 1.3. Comparison 1 Intravenous versus intraosseous access, Outcome 3 Time to infusion/placement.

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: 1 Intravenous versus intraosseous access

Outcome: 3 Time to infusion/placement

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Intraosseous</th>
<th>Mean Difference (SE)</th>
<th>Mean Difference (IV,Fixed,95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Banerjee 1994</td>
<td>20</td>
<td>40</td>
<td>62 (14.76)</td>
<td>62.00 [33.07, 90.93]</td>
</tr>
<tr>
<td>Lamhaut 2010 (no PPE)</td>
<td>25</td>
<td>25</td>
<td>20 (4.8)</td>
<td>20.00 [10.59, 29.41]</td>
</tr>
<tr>
<td>Lamhaut 2010 (with PPE)</td>
<td>25</td>
<td>25</td>
<td>39 (4)</td>
<td>39.00 [31.16, 46.84]</td>
</tr>
<tr>
<td>Reades 2011</td>
<td>67</td>
<td>115</td>
<td>8.14 (11.64)</td>
<td>8.14 [-14.67, 30.95]</td>
</tr>
</tbody>
</table>

Analysis 1.4. Comparison 1 Intravenous versus intraosseous access, Outcome 4 Average number of insertion attempts.

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: 1 Intravenous versus intraosseous access

Outcome: 4 Average number of insertion attempts

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Intraosseous</th>
<th>Mean Difference</th>
<th>Mean Difference (IV,Fixed,95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reades 2011</td>
<td>67</td>
<td>115</td>
<td>0.0</td>
<td>0.0 [-0.07, 0.07]</td>
</tr>
</tbody>
</table>
**Analysis 1.5.** Comparison 1 Intravenous versus intraosseous access, Outcome 5 Dislodgement of device during infusion.

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: 1 Intravenous versus intraosseous access

Outcome: 5 Dislodgement of device during infusion

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Intraosseous</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Fixed,95% CI</td>
<td>M-H,Fixed,95% CI</td>
</tr>
<tr>
<td>Reades 2011</td>
<td>4/67</td>
<td>13/115</td>
<td>0.53 [ 0.18, 1.55 ]</td>
<td>0.53 [ 0.18, 1.55 ]</td>
</tr>
</tbody>
</table>

Favours intravenous Favours intraosseous

---

**Analysis 1.6.** Comparison 1 Intravenous versus intraosseous access, Outcome 6 Local site reactions.

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: 1 Intravenous versus intraosseous access

Outcome: 6 Local site reactions

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Intraosseous</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Fixed,95% CI</td>
<td>M-H,Fixed,95% CI</td>
</tr>
<tr>
<td>Infection</td>
<td></td>
<td></td>
<td>5.57 [ 0.35, 88.77 ]</td>
<td>5.57 [ 0.35, 88.77 ]</td>
</tr>
<tr>
<td>Hägglund 1998</td>
<td>6/20</td>
<td>0/8</td>
<td>5.57 [ 0.35, 88.77 ]</td>
<td>5.57 [ 0.35, 88.77 ]</td>
</tr>
</tbody>
</table>

Favours intravenous Favours intraosseous
Analysis 1.7. Comparison 1 Intravenous versus intraosseous access, Outcome 7 Clinician’s perception of ease/feasibility of administration.

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: 1 Intravenous versus intraosseous access

Outcome: 7 Clinician’s perception of ease/feasibility of administration

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Intraosseous</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Fixed 95% CI</td>
<td>M-H,Fixed 95% CI</td>
</tr>
<tr>
<td>Reades 2011</td>
<td>2/67</td>
<td>23/115</td>
<td>0.15</td>
<td>[0.04, 0.61]</td>
</tr>
</tbody>
</table>

Favours intravenous

Analysis 1.8. Comparison 1 Intravenous versus intraosseous access, Outcome 8 Volume of fluids transfused.

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: 1 Intravenous versus intraosseous access

Outcome: 8 Volume of fluids transfused

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Intraosseous</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>IV,Fixed 95% CI</td>
<td>IV,Fixed 95% CI</td>
</tr>
<tr>
<td>Reades 2011</td>
<td>67</td>
<td>800 (125)</td>
<td>-400</td>
<td>400 (93.06)</td>
</tr>
</tbody>
</table>

Favours intravenous

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Analysis 1.9. Comparison 1 Intravenous versus intraosseous access, Outcome 9 Electrolyte level.

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: 1 Intravenous versus intraosseous access

Outcome: 9 Electrolyte level

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Intraosseous</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Sodium</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Banerjee 1994</td>
<td>20</td>
<td>132 (8.9)</td>
<td>40</td>
<td>133 (6.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-1.00 [ -5.36, 3.36 ]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Potassium</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Banerjee 1994</td>
<td>20</td>
<td>3.9 (5.8)</td>
<td>40</td>
<td>4.3 (1.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-0.40 [ -2.97, 2.17 ]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Higher in intraosseous Higher in intravenous

### Analysis 1.10. Comparison 1 Intravenous versus intraosseous access, Outcome 10 Renal function.

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: 1 Intravenous versus intraosseous access

Outcome: 10 Renal function

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Intraosseous</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Urea</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Banerjee 1994</td>
<td>20</td>
<td>14 (8.9)</td>
<td>40</td>
<td>19 (12.65)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-5.00 [ -10.53, 0.53 ]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Banerjee 1994</td>
<td>20</td>
<td>115 (18)</td>
<td>40</td>
<td>150 (18)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-35.00 [ -44.66, -25.34 ]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Favours intravenous Favours intraosseous
### Analysis 2.1. Comparison 2 Intravenous versus subcutaneous access, Outcome 1 Insertion failures.

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: 2 Intravenous versus subcutaneous access

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Subcutaneous</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delamaire 1992</td>
<td>4/15</td>
<td>0/15</td>
<td>33.2%</td>
<td>9.00</td>
<td>[0.53, 153.79]</td>
</tr>
<tr>
<td>O’Keeffe 1996</td>
<td>1/30</td>
<td>0/30</td>
<td>33.2%</td>
<td>3.00</td>
<td>[0.13, 70.83]</td>
</tr>
<tr>
<td>Spandorfer 2005</td>
<td>16/75</td>
<td>0/73</td>
<td>33.6%</td>
<td>32.13</td>
<td>[1.96, 525.87]</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>120</td>
<td>118</td>
<td>100.0%</td>
<td>14.79</td>
<td>[2.87, 76.08]</td>
</tr>
</tbody>
</table>

Total events: 21 (Intravenous), 0 (Subcutaneous)

Heterogeneity: Chi² = 1.39, df = 2 (P = 0.50); I² =0.0%

Test for overall effect: Z = 3.22 (P = 0.0013)

Test for subgroup differences: Not applicable

---

### Analysis 2.2. Comparison 2 Intravenous versus subcutaneous access, Outcome 2 Insertion failures

(sensitivity analysis - trial(s) with adequate allocation concealment).

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: 2 Intravenous versus subcutaneous access

Outcome: 2 Insertion failures (sensitivity analysis - trial(s) with adequate allocation concealment)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Subcutaneous</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spandorfer 2005</td>
<td>16/75</td>
<td>0/73</td>
<td>32.13 [1.96, 525.87]</td>
</tr>
</tbody>
</table>

Total events: 21 (Intravenous), 0 (Subcutaneous)

<table>
<thead>
<tr>
<th>0.002</th>
<th>0.1</th>
<th>1</th>
<th>10</th>
<th>500</th>
</tr>
</thead>
<tbody>
<tr>
<td>Favours intravenous</td>
<td>Favours subcutaneous</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease (Review)  
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.3. Comparison 2 Intravenous versus subcutaneous access, Outcome 3 Insertion failures (subgroup analysis child vs adult).

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: 2 Intravenous versus subcutaneous access

Outcome: 3 Insertion failures (subgroup analysis child vs adult)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Subcutaneous</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Fixed,95% CI</td>
<td></td>
<td>M-H,Fixed,95% CI</td>
</tr>
<tr>
<td>1 Adult</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delamaire 1992</td>
<td>4/15</td>
<td>0/15</td>
<td>33.2 %</td>
<td>9.00</td>
<td>[ 0.53, 153.79 ]</td>
</tr>
<tr>
<td>O’Keeffe 1996</td>
<td>1/30</td>
<td>0/30</td>
<td>33.2 %</td>
<td>3.00</td>
<td>[ 0.13, 70.83 ]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>45</strong></td>
<td><strong>45</strong></td>
<td></td>
<td><strong>66.4 %</strong></td>
<td><strong>6.00 [ 0.76, 47.39 ]</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Child</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spandorfer 2005</td>
<td>16/75</td>
<td>0/73</td>
<td>33.6 %</td>
<td>32.13</td>
<td>[ 1.96, 525.87 ]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>75</strong></td>
<td><strong>73</strong></td>
<td></td>
<td><strong>33.6 %</strong></td>
<td><strong>32.13 [ 1.96, 525.87 ]</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>120</strong></td>
<td><strong>118</strong></td>
<td></td>
<td><strong>100.0 %</strong></td>
<td><strong>14.79 [ 2.87, 76.08 ]</strong></td>
</tr>
</tbody>
</table>

Heterogeneity: Chi² = 0.26, df = 1 (P = 0.61); I² =0.0%
Test for overall effect: Z = 1.70 (P = 0.089)
Test for subgroup differences: Chi² = 0.90, df = 1 (P = 0.34), I² =0.0%
Analysis 2.4. Comparison 2 Intravenous versus subcutaneous access, Outcome 4 Time to infusion/placement.

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: 2 Intravenous versus subcutaneous access

Outcome: 4 Time to infusion/placement

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Subcutaneous</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Slesak 2003</td>
<td>48</td>
<td>300 (420)</td>
<td>48</td>
<td>180 (135)</td>
</tr>
</tbody>
</table>

-200 -100 0 100 200
Favours intravenous Favours subcutaneous

Analysis 2.5. Comparison 2 Intravenous versus subcutaneous access, Outcome 5 Dislodgement of device during infusion.

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: 2 Intravenous versus subcutaneous access

Outcome: 5 Dislodgement of device during infusion

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Subcutaneous</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duems Noriega 2014</td>
<td>11/33</td>
<td>3/34</td>
<td></td>
<td>3.78 [1.16, 12.34]</td>
</tr>
</tbody>
</table>

0.01 0.1 1 10 100
Favours intravenous Favours subcutaneous
### Analysis 2.6. Comparison 2 Intravenous versus subcutaneous access, Outcome 6 Time with functional access (days).

**Review:** Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease.

**Comparison:** 2 Intravenous versus subcutaneous access.

**Outcome:** 6 Time with functional access (days)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Subcutaneous</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Slesak 2003</td>
<td>48</td>
<td>2.8 (2.13)</td>
<td>48</td>
<td>2.0 (2.13)</td>
</tr>
</tbody>
</table>

### Analysis 2.7. Comparison 2 Intravenous versus subcutaneous access, Outcome 7 Local site reactions.

**Review:** Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease.

**Comparison:** 2 Intravenous versus subcutaneous access.

**Outcome:** 7 Local site reactions

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Subcutaneous</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Fixed,95% CI</td>
<td>M-H,Fixed,95% CI</td>
<td></td>
</tr>
<tr>
<td>1 Any</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boullu-Sanchis 2006</td>
<td>6/13</td>
<td>0/20</td>
<td>0.4 %</td>
<td>19.50 [ 1.19, 319.33 ]</td>
<td></td>
</tr>
<tr>
<td>Challiner 1994</td>
<td>1/17</td>
<td>2/19</td>
<td>2.1 %</td>
<td>0.56 [ 0.06, 5.63 ]</td>
<td></td>
</tr>
<tr>
<td>Harbo 2009</td>
<td>3/9</td>
<td>6/9</td>
<td>6.7 %</td>
<td>0.50 [ 0.08, 1.40 ]</td>
<td></td>
</tr>
<tr>
<td>Selam 1983</td>
<td>1/6</td>
<td>6/6</td>
<td>7.3 %</td>
<td>0.23 [ 0.06, 0.97 ]</td>
<td></td>
</tr>
<tr>
<td>Spandorfer 2005</td>
<td>68/75</td>
<td>73/73</td>
<td>83.4 %</td>
<td>0.91 [ 0.84, 0.98 ]</td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>120</strong></td>
<td><strong>127</strong></td>
<td><strong>100.0 %</strong></td>
<td><strong>0.91 [ 0.80, 1.02 ]</strong></td>
<td></td>
</tr>
</tbody>
</table>

Total events: 79 (Intravenous), 87 (Subcutaneous)

Heterogeneity: Chi² = 9.57, df = 4 (P = 0.05); I² = 58%

Test for overall effect: Z = 1.60 (P = 0.11)

2 Erythema

(Continued...)
### Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease (Review)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous n/N</th>
<th>Subcutaneous n/N</th>
<th>Risk Ratio M-H Fixed 95% CI</th>
<th>Weight M-H Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Challiner 1994</td>
<td>0/17</td>
<td>1/17</td>
<td>2.1 % 0.33 [0.01, 7.65]</td>
<td>1</td>
</tr>
<tr>
<td>Harbo 2009</td>
<td>0/9</td>
<td>4/9</td>
<td>6.4 % 0.11 [0.01, 1.80]</td>
<td>1</td>
</tr>
<tr>
<td>Slesak 2003</td>
<td>11/48</td>
<td>10/48</td>
<td>14.1 % 1.10 [0.52, 2.35]</td>
<td>1</td>
</tr>
<tr>
<td>Spandorfer 2005</td>
<td>19/75</td>
<td>54/73</td>
<td>77.4 % 0.34 [0.23, 0.52]</td>
<td>1</td>
</tr>
</tbody>
</table>

**Subtotal (95% CI)** 149 147 100.0 % 0.43 [0.31, 0.61]

Total events: 30 (Intravenous), 69 (Subcutaneous)
Heterogeneity: Chi² = 8.01, df = 3 (P = 0.05); I² = 63%
Test for overall effect: Z = 4.71 (P < 0.00001)

3 Swelling

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous n/N</th>
<th>Subcutaneous n/N</th>
<th>Risk Ratio M-H Fixed 95% CI</th>
<th>Weight M-H Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spandorfer 2005</td>
<td>16/75</td>
<td>59/73</td>
<td>100.0 % 0.26 [0.17, 0.41]</td>
<td>1</td>
</tr>
</tbody>
</table>

**Subtotal (95% CI)** 75 73 100.0 % 0.26 [0.17, 0.41]

Total events: 16 (Intravenous), 59 (Subcutaneous)
Heterogeneity: not applicable
Test for overall effect: Z = 5.82 (P < 0.00001)

4 Infection

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous n/N</th>
<th>Subcutaneous n/N</th>
<th>Risk Ratio M-H Fixed 95% CI</th>
<th>Weight M-H Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delmaire 1992</td>
<td>7/15</td>
<td>0/15</td>
<td>16.8 % 15.00 [0.93, 241.20]</td>
<td>1</td>
</tr>
<tr>
<td>Duems Noriega 2014</td>
<td>0/33</td>
<td>1/34</td>
<td>49.6 % 0.34 [0.01, 8.13]</td>
<td>1</td>
</tr>
<tr>
<td>Harbo 2009</td>
<td>1/9</td>
<td>0/9</td>
<td>16.8 % 3.00 [0.14, 65.16]</td>
<td>1</td>
</tr>
<tr>
<td>Slesak 2003</td>
<td>1/48</td>
<td>0/48</td>
<td>16.8 % 3.00 [0.13, 71.85]</td>
<td>1</td>
</tr>
</tbody>
</table>

**Subtotal (95% CI)** 105 106 100.0 % 3.70 [1.06, 12.88]

Total events: 9 (Intravenous), 1 (Subcutaneous)
Heterogeneity: Chi² = 3.18, df = 3 (P = 0.37); I² = 6%
Test for overall effect: Z = 2.05 (P = 0.040)

5 Phlebitis

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous n/N</th>
<th>Subcutaneous n/N</th>
<th>Risk Ratio M-H Fixed 95% CI</th>
<th>Weight M-H Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duems Noriega 2014</td>
<td>2/33</td>
<td>0/34</td>
<td>24.7 % 5.15 [0.26, 103.33]</td>
<td>1</td>
</tr>
<tr>
<td>Harbo 2009</td>
<td>1/9</td>
<td>0/9</td>
<td>25.1 % 3.00 [0.14, 65.16]</td>
<td>1</td>
</tr>
<tr>
<td>Slesak 2003</td>
<td>6/48</td>
<td>1/48</td>
<td>50.2 % 6.00 [0.75, 47.97]</td>
<td>1</td>
</tr>
</tbody>
</table>

**Subtotal (95% CI)** 90 91 100.0 % 5.04 [1.14, 22.30]

Total events: 9 (Intravenous), 1 (Subcutaneous)
Heterogeneity: Chi² = 0.14, df = 2 (P = 0.93); I² = 0.0%
Test for overall effect: Z = 2.13 (P = 0.033)

6 Oedema

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous n/N</th>
<th>Subcutaneous n/N</th>
<th>Risk Ratio M-H Fixed 95% CI</th>
<th>Weight M-H Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Challiner 1994</td>
<td>0/17</td>
<td>1/19</td>
<td>3.7 % 0.37 [0.02, 8.53]</td>
<td>1</td>
</tr>
<tr>
<td>Delmaire 1992</td>
<td>0/15</td>
<td>3/15</td>
<td>9.2 % 0.14 [0.01, 2.55]</td>
<td>1</td>
</tr>
<tr>
<td>Duems Noriega 2014</td>
<td>2/33</td>
<td>5/34</td>
<td>13.0 % 0.41 [0.09, 1.98]</td>
<td>1</td>
</tr>
<tr>
<td>Harbo 2009</td>
<td>0/9</td>
<td>1/9</td>
<td>4.0 % 0.33 [0.02, 7.24]</td>
<td>1</td>
</tr>
<tr>
<td>O’Keeffe 1996</td>
<td>0/29</td>
<td>2/29</td>
<td>6.6 % 0.20 [0.01, 3.99]</td>
<td>1</td>
</tr>
<tr>
<td>Slesak 2003</td>
<td>11/48</td>
<td>19/48</td>
<td>50.1 % 0.58 [0.31, 1.08]</td>
<td>1</td>
</tr>
</tbody>
</table>

© 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Analysis 2.8. Comparison 2 Intravenous versus subcutaneous access, Outcome 8 Local site reactions (sensitivity analysis - trial(s) with adequate allocation concealment).

**Review:** Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

**Comparison:** 2 Intravenous versus subcutaneous access

**Outcome:** 8 Local site reactions (sensitivity analysis - trial(s) with adequate allocation concealment)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous n/N</th>
<th>Subcutaneous n/N</th>
<th>Risk Ratio M-H,Fixed,95% CI</th>
<th>Weight</th>
<th>Risk Ratio M-H,Fixed,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Any</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Challiner 1994</td>
<td>1/17</td>
<td>2/19</td>
<td>2.3 % 0.56 [0.06, 5.63]</td>
<td>0.56</td>
<td></td>
</tr>
<tr>
<td>Harbo 2009</td>
<td>3/9</td>
<td>6/9</td>
<td>7.3 % 0.50 [0.18, 1.40]</td>
<td>0.50</td>
<td></td>
</tr>
<tr>
<td>Spandorfer 2005</td>
<td>68/75</td>
<td>73/73</td>
<td>90.4 % 0.91 [0.84, 0.98]</td>
<td>0.91</td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>101</strong></td>
<td><strong>101</strong></td>
<td>100.0 % 0.87 [0.79, 0.96]</td>
<td>0.87</td>
<td></td>
</tr>
<tr>
<td>2 Erythema</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Challiner 1994</td>
<td>0/17</td>
<td>1/17</td>
<td>2.5 % 0.33 [0.01, 7.65]</td>
<td>0.33</td>
<td></td>
</tr>
<tr>
<td>Harbo 2009</td>
<td>0/9</td>
<td>4/9</td>
<td>7.4 % 0.11 [0.01, 1.80]</td>
<td>0.11</td>
<td></td>
</tr>
<tr>
<td>Spandorfer 2005</td>
<td>19/75</td>
<td>54/73</td>
<td>90.1 % 0.34 [0.23, 0.52]</td>
<td>0.34</td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>101</strong></td>
<td><strong>99</strong></td>
<td>100.0 % 0.33 [0.22, 0.49]</td>
<td>0.33</td>
<td></td>
</tr>
<tr>
<td>Study or subgroup</td>
<td>Intravenous</td>
<td>Subcutaneous</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Weight</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
</tr>
<tr>
<td>------------------</td>
<td>-------------</td>
<td>--------------</td>
<td>--------------------------------</td>
<td>--------</td>
<td>------------------------------</td>
</tr>
<tr>
<td><strong>Total events:</strong> 19 (Intravenous), 59 (Subcutaneous)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Heterogeneity:</strong> Chi² = 0.63, df = 2 (P = 0.73); I² =0.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 5.41 (P &lt; 0.00001)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>3 Swelling</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spandorfer 2005</td>
<td>16/75</td>
<td>59/73</td>
<td><img src="0" alt="node" /></td>
<td>100.0 %</td>
<td>0.26 [0.17, 0.41]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI):</strong></td>
<td>75</td>
<td>73</td>
<td><img src="0" alt="node" /></td>
<td>100.0 %</td>
<td>0.26 [0.17, 0.41]</td>
</tr>
<tr>
<td><strong>Total events:</strong> 16 (Intravenous), 59 (Subcutaneous)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Heterogeneity:</strong> not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 5.82 (P &lt; 0.00001)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>4 Infection</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harbo 2009</td>
<td>1/9</td>
<td>0/9</td>
<td><img src="0" alt="node" /></td>
<td>100.0 %</td>
<td>3.00 [0.14, 65.16]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI):</strong></td>
<td>9</td>
<td>9</td>
<td><img src="0" alt="node" /></td>
<td>100.0 %</td>
<td>3.00 [0.14, 65.16]</td>
</tr>
<tr>
<td><strong>Total events:</strong> 1 (Intravenous), 0 (Subcutaneous)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Heterogeneity:</strong> not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 0.70 (P = 0.48)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>5 Phlebitis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harbo 2009</td>
<td>1/9</td>
<td>0/9</td>
<td><img src="0" alt="node" /></td>
<td>100.0 %</td>
<td>3.00 [0.14, 65.16]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI):</strong></td>
<td>9</td>
<td>9</td>
<td><img src="0" alt="node" /></td>
<td>100.0 %</td>
<td>3.00 [0.14, 65.16]</td>
</tr>
<tr>
<td><strong>Total events:</strong> 1 (Intravenous), 0 (Subcutaneous)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Heterogeneity:</strong> not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 0.70 (P = 0.48)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>6 Oedema</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Challiner 1994</td>
<td>0/17</td>
<td>1/19</td>
<td><img src="0" alt="node" /></td>
<td>17.8 %</td>
<td>0.37 [0.02, 8.53]</td>
</tr>
<tr>
<td>Harbo 2009</td>
<td>0/9</td>
<td>1/9</td>
<td><img src="0" alt="node" /></td>
<td>18.8 %</td>
<td>0.33 [0.02, 7.24]</td>
</tr>
<tr>
<td>Spandorfer 2005</td>
<td>1/75</td>
<td>5/73</td>
<td><img src="0" alt="node" /></td>
<td>63.4 %</td>
<td>0.19 [0.02, 1.63]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI):</strong></td>
<td>101</td>
<td>101</td>
<td><img src="0" alt="node" /></td>
<td>100.0 %</td>
<td>0.25 [0.06, 1.15]</td>
</tr>
<tr>
<td><strong>Total events:</strong> 1 (Intravenous), 7 (Subcutaneous)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Heterogeneity:</strong> Chi² = 0.15, df = 2 (P = 0.93); I² =0.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 1.78 (P = 0.075)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for subgroup differences: Chi² = 48.25, df = 5 (P = 0.00), I² =90%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Analysis 2.9. Comparison 2 Intravenous versus subcutaneous access, Outcome 9 Clinicians’ scores of feasibility of insertion.

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: 2 Intravenous versus subcutaneous access

Outcome: 9 Clinicians’ scores of feasibility of insertion

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Subcutaneous</th>
<th>Mean Difference</th>
<th>IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doctors’ scores</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slesak 2003</td>
<td>48</td>
<td>2 (0.47)</td>
<td>48</td>
<td>2 (0.19)</td>
</tr>
<tr>
<td>Nurses’ scores</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slesak 2003</td>
<td>43</td>
<td>2 (0.313)</td>
<td>44</td>
<td>2 (0.25)</td>
</tr>
</tbody>
</table>

### Analysis 2.10. Comparison 2 Intravenous versus subcutaneous access, Outcome 10 Clinician’s perception of difficulty of insertion.

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: 2 Intravenous versus subcutaneous access

Outcome: 10 Clinician’s perception of difficulty of insertion

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Subcutaneous</th>
<th>Risk Ratio</th>
<th>M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spandorfer 2005</td>
<td>26/75</td>
<td>4/73</td>
<td>6.33</td>
<td>[2.32, 17.23]</td>
</tr>
</tbody>
</table>
### Analysis 2.11. Comparison 2 Intravenous versus subcutaneous access, Outcome 11 Patients’ discomfort.

**Review:** Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

**Comparison:** 2 Intravenous versus subcutaneous access

**Outcome:** 11 Patients’ discomfort

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Subcutaneous</th>
<th>Risk Ratio M-H,Fixed, 95% CI</th>
<th>Weight</th>
<th>Risk Ratio M-H,Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Pain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harbo 2009</td>
<td>0/9</td>
<td>3/9</td>
<td></td>
<td>5.3 %</td>
<td>0.14 [ 0.01, 2.42 ]</td>
</tr>
<tr>
<td>Slesak 2003</td>
<td>8/48</td>
<td>6/48</td>
<td></td>
<td>9.1 %</td>
<td>1.33 [ 0.50, 3.55 ]</td>
</tr>
<tr>
<td>Spandorfer 2005</td>
<td>59/75</td>
<td>56/73</td>
<td></td>
<td>85.7 %</td>
<td>1.03 [ 0.86, 1.22 ]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>132</strong></td>
<td><strong>130</strong></td>
<td></td>
<td><strong>100.0 %</strong></td>
<td><strong>1.01 [ 0.83, 1.22 ]</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Agitation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duems Noriega 2014</td>
<td>16/33</td>
<td>11/34</td>
<td></td>
<td>49.6 %</td>
<td>1.50 [ 0.82, 2.73 ]</td>
</tr>
<tr>
<td>O'Keeffe 1996</td>
<td>24/29</td>
<td>11/29</td>
<td></td>
<td>50.4 %</td>
<td>2.18 [ 1.33, 3.58 ]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>62</strong></td>
<td><strong>63</strong></td>
<td></td>
<td><strong>100.0 %</strong></td>
<td><strong>1.84 [ 1.26, 2.70 ]</strong></td>
</tr>
</tbody>
</table>

**Total events:** 67 (Intravenous), 65 (Subcutaneous)

**Heterogeneity:** Chi² = 2.19, df = 2 (P = 0.33); I² = 9%

**Test for overall effect:** Z = 0.07 (P = 0.94)

**0.01 0.1 1 10 100**

---

*Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease (Review)*

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.12. Comparison 2 Intravenous versus subcutaneous access, Outcome 12 Patients' discomfort (sensitivity analysis - trial(s) with adequate allocation concealment).

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: 2 Intravenous versus subcutaneous access

Outcome: 12 Patients' discomfort (sensitivity analysis - trial(s) with adequate allocation concealment)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Subcutaneous</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Fixed,95% CI</td>
<td></td>
<td>M-H,Fixed,95% CI</td>
</tr>
<tr>
<td>1 Pain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harbo 2009</td>
<td>0/9</td>
<td>3/9</td>
<td>5.8 %</td>
<td>0.14 [ 0.01, 2.42 ]</td>
<td></td>
</tr>
<tr>
<td>Spandorfer 2005</td>
<td>59/75</td>
<td>56/73</td>
<td>94.2 %</td>
<td>1.03 [ 0.86, 1.22 ]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>84</td>
<td>82</td>
<td>100.0 %</td>
<td>0.97 [ 0.81, 1.16 ]</td>
<td></td>
</tr>
</tbody>
</table>

Total events: 59 (Intravenous), 59 (Subcutaneous)
Heterogeneity: Chi² = 2.11, df = 1 (P = 0.15); I² = 53% Test for overall effect: Z = 0.29 (P = 0.77)

Analysis 2.13. Comparison 2 Intravenous versus subcutaneous access, Outcome 13 Patient discomfort score.

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: 2 Intravenous versus subcutaneous access

Outcome: 13 Patient discomfort score

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Subcutaneous</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>IV,Fixed,95% CI</td>
<td>IV,Fixed,95% CI</td>
</tr>
<tr>
<td>Slesak 2003</td>
<td>28</td>
<td>2 (0.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>26</td>
<td>2 (0.25)</td>
<td>0.0 [ -0.21, 0.21 ]</td>
<td></td>
</tr>
</tbody>
</table>

Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease (Review) 75
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Analysis 2.14. Comparison 2 Intravenous versus subcutaneous access, Outcome 14 Mortality.

**Review:** Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

**Comparison:** 2 Intravenous versus subcutaneous access

**Outcome:** 14 Mortality

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Subcutaneous</th>
<th>Risk Ratio (M-H, Fixed 95% CI)</th>
<th>Weight</th>
<th>Risk Ratio (M-H, Fixed 95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Challiner 1994</td>
<td>0/17</td>
<td>1/19</td>
<td>0.37 [0.02, 8.53]</td>
<td>58.7%</td>
<td>0.37 [0.02, 8.53]</td>
</tr>
<tr>
<td>Duems Noriega 2014</td>
<td>2/35</td>
<td>1/35</td>
<td>2.00 [0.19, 21.06]</td>
<td>41.3%</td>
<td>2.00 [0.19, 21.06]</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>52</strong></td>
<td><strong>54</strong></td>
<td><strong>1.04 [0.18, 5.92]</strong></td>
<td><strong>100.0%</strong></td>
<td><strong>1.04 [0.18, 5.92]</strong></td>
</tr>
</tbody>
</table>

Total events: 2 (Intravenous), 2 (Subcutaneous)

Heterogeneity: Chi$^2 = 0.71$, df = 1 ($P = 0.40$); $I^2 = 0.0$

Test for overall effect: $Z = 0.05$ ($P = 0.96$)

Test for subgroup differences: Not applicable

---

### Analysis 2.15. Comparison 2 Intravenous versus subcutaneous access, Outcome 15 Mortality (sensitivity analysis - trial(s) with adequate allocation concealment).

**Review:** Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

**Comparison:** 2 Intravenous versus subcutaneous access

**Outcome:** 15 Mortality (sensitivity analysis - trial(s) with adequate allocation concealment)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Subcutaneous</th>
<th>Risk Ratio (M-H, Fixed 95% CI)</th>
<th>Risk Ratio (M-H, Fixed 95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Challiner 1994</td>
<td>0/17</td>
<td>1/19</td>
<td>0.37 [0.02, 8.53]</td>
<td>0.37 [0.02, 8.53]</td>
</tr>
</tbody>
</table>

---

**Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease (Review)**

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
**Analysis 2.16. Comparison 2 Intravenous versus subcutaneous access, Outcome 16 Volume of fluids transfused.**

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: Intravenous versus subcutaneous access

Outcome: Volume of fluids transfused

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Subcutaneous</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Duems Noriega 2014</td>
<td>33</td>
<td>1480 (340)</td>
<td>34</td>
<td>1320 (400)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IV,Fixed,95% CI</td>
</tr>
<tr>
<td>O'Keeffe 1996</td>
<td>29</td>
<td>760 (140)</td>
<td>29</td>
<td>820 (120)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IV,Fixed,95% CI</td>
</tr>
<tr>
<td>Slesak 2003</td>
<td>48</td>
<td>1000 (250)</td>
<td>48</td>
<td>750 (260.8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IV,Fixed,95% CI</td>
</tr>
<tr>
<td>Spandorfer 2005</td>
<td>75</td>
<td>455.8 (597.4)</td>
<td>73</td>
<td>365 (324.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IV,Fixed,95% CI</td>
</tr>
</tbody>
</table>

**Analysis 2.17. Comparison 2 Intravenous versus subcutaneous access, Outcome 17 Volume of fluids transfused (sensitivity analysis - trial(s) with adequate allocation).**

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: Intravenous versus subcutaneous access

Outcome: Volume of fluids transfused (sensitivity analysis - trial(s) with adequate allocation)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Subcutaneous</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IV,Fixed,95% CI</td>
</tr>
<tr>
<td>Spandorfer 2005</td>
<td>75</td>
<td>455.8 (597.4)</td>
<td>73</td>
<td>365 (324.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>IV,Fixed,95% CI</td>
</tr>
</tbody>
</table>
Analysis 2.18. Comparison 2 Intravenous versus subcutaneous access, Outcome 18 Electrolyte level.

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: 2 Intravenous versus subcutaneous access

Outcome: 18 Electrolyte level

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Subcutaneous</th>
<th>Mean Difference</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N Mean (SD)</td>
<td>N Mean (SD)</td>
<td>IV Fixed 95% CI</td>
<td></td>
</tr>
<tr>
<td>Sodium</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slesak 2003</td>
<td>37 139 (5)</td>
<td>40 137 (5)</td>
<td>2.00 [-0.24, 4.24]</td>
<td></td>
</tr>
</tbody>
</table>

Higher in subcutaneous

Analysis 2.19. Comparison 2 Intravenous versus subcutaneous access, Outcome 19 Markers of renal function.

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: 2 Intravenous versus subcutaneous access

Outcome: 19 Markers of renal function

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Subcutaneous</th>
<th>Mean Difference</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N Mean (SD)</td>
<td>N Mean (SD)</td>
<td>IV Fixed 95% CI</td>
<td></td>
</tr>
<tr>
<td>Urea</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duems Noriega 2014</td>
<td>33 52.3 (23.8)</td>
<td>34 63.59 (31.7)</td>
<td>-11.29 [-24.69, 2.11]</td>
<td>100.0 %</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>33</td>
<td>34</td>
<td>-11.29 [-24.69, 2.11]</td>
<td>100.0 %</td>
</tr>
</tbody>
</table>

Heterogeneity: not applicable

Test for overall effect: Z = 1.65 (P = 0.099)

2 Creatinine

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Intravenous</th>
<th>Subcutaneous</th>
<th>Mean Difference</th>
<th>Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N Mean (SD)</td>
<td>N Mean (SD)</td>
<td>IV Fixed 95% CI</td>
<td></td>
</tr>
<tr>
<td>Duems Noriega 2014</td>
<td>33 0.6 (0.49)</td>
<td>34 0.68 (0.66)</td>
<td>-0.08 [-0.36, 0.20]</td>
<td>79.8 %</td>
</tr>
<tr>
<td>Slesak 2003</td>
<td>31 0.8 (0.73)</td>
<td>40 0.9 (1.58)</td>
<td>-0.10 [-0.65, 0.45]</td>
<td>20.2 %</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>64</td>
<td>74</td>
<td>-0.08 [-0.33, 0.16]</td>
<td>100.0 %</td>
</tr>
</tbody>
</table>

Heterogeneity: Chi² = 0.00, df = 1 (P = 0.95); I² = 0.0%

Test for overall effect: Z = 0.66 (P = 0.51)

Test for subgroup differences: Chi² = 2.69, df = 1 (P = 0.10), I² = 63%
Analysis 3.1. **Comparison 3 Saphenous vein cutdown versus intraosseous access, Outcome 1 Insertion failures.**

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: 3 Saphenous vein cutdown versus intraosseous access

Outcome: 1 Insertion failures

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Saphenous vein cutdown n/N</th>
<th>Intraosseous n/N</th>
<th>Risk Ratio M-H,Fixed,95% CI</th>
<th>Risk Ratio M-H,Fixed,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hubble 2001</td>
<td>4/13</td>
<td>1/13</td>
<td>4.00 [0.51, 31.13]</td>
<td></td>
</tr>
</tbody>
</table>

Favours Saphenous vein cutdown

Analysis 3.2. **Comparison 3 Saphenous vein cutdown versus intraosseous access, Outcome 2 Time to infusion/placement (seconds).**

Review: Comparison of routes for achieving parenteral access with a focus on the management of patients with Ebola virus disease

Comparison: 3 Saphenous vein cutdown versus intraosseous access

Outcome: 2 Time to infusion/placement (seconds)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Mean Difference (SE)</th>
<th>Mean Difference (SE) IV,Fixed,95% CI</th>
<th>Mean Difference (SE) IV,Fixed,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hubble 2001</td>
<td>219.6 (42.94)</td>
<td>219.60 [135.44, 303.76]</td>
<td></td>
</tr>
</tbody>
</table>

Favours SVC

Favours intraosseous
APPENDICES

Appendix 1. Search strategies

Cochrane Injuries Group Specialised Register & Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library)

#1((Intravenous or venous) ADJ3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*)):TI,AB,KY
#2MESH DESCRIPTOR Infusions, Intravenous
#3#1 OR #2
#4((intraperitoneal*) ADJ3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus* or dehydrat* or hydrat* or rehydrat* or drug* or medication*)):TI,AB,KY
#5MESH DESCRIPTOR Infusions, Intraosseous
#6(intraosseous*) ADJ3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus* or dehydrat* or hydrat* or rehydrat* or drug* or medication*)
#7#5 OR #6
#8MESH DESCRIPTOR Infusions, Subcutaneous
#9MESH DESCRIPTOR Hypodermoclysis
#10((subcutaneous* or hypodermoclysis) ADJ3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*)):TI,AB,KY
#11#8 OR #9 OR #10
#12#4 OR #7 OR #11
#13#3 AND #12
#14#3 OR #7 OR #11
#15#4 AND #14
#16#3 OR #4 OR #11
#17#7 AND #16
#18#3 OR #4 OR #7
#19#11 AND #18
#20#13 OR #15 OR #17 OR #19
#21* NOT INMEDLINE NOT INEMBASE
#22#20 AND #21

Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily, Ovid MEDLINE(R) and Ovid OLDMEDLINE(R)

1. Infusions, Intravenous/
2. ("(intra?venous*" or venous) adj3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*)).ab,ti.
3. 1 or 2
4. ("(intra?peritoneal*" adj3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus* or dehydrat* or hydrat* or rehydrat* or drug* or medication*)).ab,ti.
5. Infusions, Intravenous/
6. ("(intra?osseous*" adj3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus* or dehydrat* or hydrat* or rehydrat* or drug* or medication*)).ab,ti.
7. 5 or 6
8. infusions, subcutaneous/ or hypodermoclysis/
9. ((subcutaneous* or subcut or hypodermoclysis) adj3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*)).ab,ti.
10. 8 or 9
11. 4 or 7 or 10
12. 3 and 11
13. 3 or 7 or 10
14. 4 and 13
15. 3 or 4 or 10
16. 7 and 15
17. 3 or 4 or 7
18. 10 and 17
19. 12 or 14 or 16 or 18
20. randomized.ab,ti.
21. randomized controlled trial.pt.
22. controlled clinical trial.pt.
23. placebo.ab.
24. clinical trials as topic.sh.
25. randomly.ab.
26. trial.ti.
27. Comparative Study/
28. 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27
29. (animals not (humans and animals)).sh.
30. 28 not 29
31. 19 and 30

**Embase + Embase Classic**
1. Infusions, Intravenous/
2. (“intra?venous” or venous) adj3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*)).ab,ti.
3. 1 or 2
4. (“intra?peritoneal” adj3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus* or dehydrat* or hydrat* or rehydrat* or drug* or medication*)).ab,ti.
5. Infusions, Intravenous/
6. (“intra?osseous” adj3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus* or dehydrat* or hydrat* or drug* or medication*)).ab,ti.
7. 5 or 6
8. infusions, subcutaneous/ or hypodermoclysis/
9. ((subcutaneous* or subcut or hypodermoclysis) adj3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus* or dehydrat* or hydrat* or drug* or medication*)).ab,ti.
10. 8 or 9
11. 4 or 7 or 10
12. 3 and 11
13. 3 or 7 or 10
14. 4 and 13
15. 3 or 4 or 10
16. 7 and 15
17. 3 or 4 or 7
18. 10 and 17
19. 12 or 14 or 16 or 18
20. exp Randomized Controlled Trial/
21. exp controlled clinical trial/
22. exp controlled study/
23. comparative study/
24. randomized.ab,ti.
25. placebo.ab.
26. *Clinical Trial/
27. exp major clinical study/
28. randomly.ab.
29. (trial or study).ti.
30. 20 or 21 or 22 or 24 or 25 or 26 or 27 or 28 or 29
31. exp animal/ not (exp human/ and exp animal/)
32. 30 not 31
33. 19 and 32
34. limit 33 to exclude medline journals

CINAHL Plus (EBSCO)

S1  (MH "Clinical Trials")
S2  PT clinical trial*
S3  TX clinical N3 trial*
S4  TI ((singl* N3 blind*) or (doubl* N3 blind*) or (trebl* N3 blind*) or (tripl* N3 blind*)) or TI ((singl* N3 mask*) or (doubl* N3 mask*) or (trebl* N3 mask*) or (tripl* N3 mask*)) or AB ((singl* N3 blind*) or (doubl* N3 blind*) or (trebl* N3 blind*) or (tripl* N3 blind*)) or AB ((singl* N3 mask*) or (doubl* N3 mask*) or (trebl* N3 mask*) or (tripl* N3 mask*))
S5  TX randomi?ed N3 control* N3 trial*
S6  (MH "Placebos")
S7  TX placebo*
S8  (MH "Random Assignment")
S9  TX random* N3 allocat*
S10 MH quantitative studies
S11 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10
S12 (MH "Infusions, Intravenous")
S13 TI (intravenous N3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*))
S14 AB (intravenous N3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*))
S15 S12 OR S13 OR S14
S16 TI intraperitoneal* N3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*)
S17 AB intraperitoneal* N3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*)
S18 S16 OR S17
S19 (MH "Infusions, Intraosseous")
S20 TI intraosseous* N3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*)
S21  AB intraosseous* N3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*)

S22  S19 OR S20 OR S21

S23  (MH “Infusions, Subcutaneous”)

S24  (MH “Hypodermoclysis”)

S25  TI (subcutaneous* or hypodermoclysis) N3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*)

S26  AB (subcutaneous* or hypodermoclysis) N3 (route* or access* or insert* or device* or method* or fluid* or therap* or administer* or administrat* or infus* or dehydrat* or rehydrat* or hydrat* or drug* or medication*)

S27  S23 OR S24 OR S25 OR S26

S28  S18 OR S22 OR S27

S29  S15 AND S28

S30  S15 OR S22 OR S27

S31  S18 AND S30

S32  S15 OR S18 OR S27

S33  S22 AND S32

S34  S15 OR S18 OR S22

S35  S27 AND S34

S36  S29 OR S31 OR S33 OR S35

S37  S11 AND S36 Limiters - Exclude MEDLINE records

Clinicaltrials.gov
(subcutaneous OR rectal OR proctoclysis OR intraosseous ) AND INFLECT EXACT “Interventional” [STUDY-TYPES] AND fluids [TREATMENT]
Appendix 2. Formulae to estimate mean and standard deviation from median, range and sample size as recommended by Hozo et al

Estimation of mean
If sample size is > 25, median can be used to estimate mean.

Estimation of standard deviation (SD)
If moderate sample size (15 < n ≤ 70) estimated SD = range/4.
If large sample size (n > 70) estimated SD = range/6.  
(Hozo 2005).

Contributions of Authors
All authors contributed to the development of the protocol and the review.

Disclosures of Interest
KK, GT, DB and HS have no known conflicts of interest.
AP: My institution receives financial support for trials from Fresenius Kabi and CSL Behring.
TH: My institution receives financial support for trials from Fresenius Kabi and CSL Behring.
IR: We (the Cochrane Injuries Group) received a small grant from The Cochrane Collaboration to complete this Cochrane Review.

Sources of Support

Internal sources
- Clinical Trials Unit, London School of Hygiene & Tropical Medicine, UK.
- National Institute for Health Research, UK.
The Cochrane Injuries Group editorial base is supported by funds from the NIHR and Professor Ian Roberts is a recipient of a NIHR Senior Investigator Award.

External sources
- The Cochrane Collaboration, UK.
The Cochrane Editorial Unit provided financial support towards the completion of this review and the accompanying film.

Differences Between Protocol and Review
We added further details to the Types of studies and Types of participants sections. These changes do not represent a change in the inclusion criteria between the protocol and review, but have been made based on the recommendations in editorial comments on the completed review to improve clarity.

We have included a paragraph to describe how data from cluster-randomised controlled trials would be included in the analysis.

At the request of the Cochrane Editorial Unit editors, we refined the outcomes included in the ‘Summary of findings’ tables and GRADE assessment. Rather than including all outcomes as originally proposed, only outcomes most closely aligned with the objectives of the review are included (success of route of placement; time to placement/start of infusion; dislodgement of device during infusion; volume of fluid infused and needlestick injuries).